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Head and neck cancer
Head and neck cancer is a serious healthcare problem that poses a considerable challenge 
to patients and health care providers. Head and neck cancers have an estimated yearly 
incidence worldwide of more than 600.000 new cases, and are among the most common 
cancers in men.1 The mortality related to this cancer type is high and about 250.000 patients 
die each year. 
The yearly incidence of head and neck cancers in the Netherlands is about 2800 and still 
growing.(Fig.1) Head and neck cancers are associated with lifestyle and environmental risk 
factors. Tobacco and alcohol use are the most important causative factors for developing 
head and neck cancer.2 The sexually transmitted human papilloma virus is also a risk factor 
for head and neck cancer, especially for oropharyngeal carcinomas.3
Intake of non-starchy vegetables and fruits in general may protect against cancers of the 
mouth, pharynx and larynx.4,5
Figure 1. Incidence by tumor location for head and neck cancers from 1990 to 2010. (The Netherlands Cancer 
Registry. www.cijfersoverkanker.nl) 
The locations of head and neck cancer include nasopharynx, oral cavity, oropharynx, 
hypopharynx, larynx, nasal cavity and paranasal sinuses and salivary glands.(Fig. 2) 
 
Figure 2. Head and neck anatomy. 
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An important component in head and neck cancer diagnosis, is tumor staging. The TNM system 
is an uniform instrument for oncology health professionals and serves as a basis for decision 
making on management of individual patients. Each individual aspect of TNM is termed in 
categories: T category describes the size and extensions of the primary tumor site, N category 
describes the regional lymph node involvement and M category describes the presence 
of distant metastatic spread. TNM combinations correspond to one of six stages.6(Fig. 3) 
T1 T2 T3 T4a T4b 
N0 I  II 
N1 III 
N2 IVa 
N3 IVb 
M1 IVc 
Figure 3. UICC tumor staging.6
The type of treatment given for head and neck cancer depends on the tumor location, stage, 
histology and the condition of the patient. Potential curative treatment consists of surgery, 
radiotherapy, and/or chemotherapy. Over the last decade, new treatment protocols have arisen 
such as surgical approaches based on pre-operative imaging facilities and image and function 
based reconstructive techniques.7,8 Also non-surgical (combined) treatment modalities, such 
as intensity modulated radiotherapy, accelerated radiotherapy, radiotherapy with hypoxic 
modification, concomitant chemoradiation and radiotherapy combined with targeted therapies 
have been developed.9-11(Fig. 4) These therapies are beneficial in terms of locoregional tumor 
control and some also for overall survival.12,13 Chemoradiation is the recommended therapy 
for more advanced tumors (T3-4).
14,15 Although this therapy offers increased organ preservation 
and is associated with progression-free and overall survival, it also increases toxicity and can 
compromise organ function. Dysphagia is one of the most recognized toxicities, which affects 
eating ability, and can lead to malnutrition.16-19
Figure 4. Incidence of treatment strategies for head and neck cancers from 2005 to 2010 (tumor stages >I)6 (The 
Netherlands Cancer Registry)
10
Chapter 1
Malnutrition in cancer patients
Malnutrition is a nutritional status in which a deficiency or imbalance of energy, protein, 
and other nutrients has measurable adverse effects on tissue/body form (shape, size, and 
composition), function, and clinical outcome.20 The prevalence of malnutrition in oncologic 
patients varies from 0 to 60%, depending on various oncology-related factors (tumor type, 
stage, treatment, treatment phase). Figures also depend on the criteria used for malnutrition, 
such as weight loss, low body mass index (BMI), decreased fat-free mass, diminished dietary 
intake, deteriorated biochemical values or a combination of these.21-24 The most frequently used 
definition for malnutrition is ≥5% weight loss in 1 month and/or ≥10% weight loss in 6 months, 
and/or a BMI of ≤18.5 kg/m2 (for age ≥65 years, BMI≤20 kg/m2), and/or in combination with 
decreased nutritional intake. Discussions in expert meetings on which criteria are essential to 
define malnutrition are ongoing.23,24
There are a number of factors that lead to a compromised nutritional health status in 
patients with cancer. Nutritional intake in patients with a malignancy is negatively affected 
by factors such as anorexia, pain, fatigue, and anxiety. Depending on tumor location and 
treatment, gastrointestinal symptoms such as nausea, vomiting, restrictions in food passage, 
constipation, diarrhea, and altered absorption may also be present.25,26 Apart from inadequate 
food intake, cachexia plays a role in malnutrition due to the cancer. Cancer can, in some 
ways, be compared with chronic inflammation. A malignant tumor can produce cytokines, like 
interleukins (IL-1, IL-6) and TNF-α and the liver responds to these cytokines with increased 
acute-phase proteins, like C-reactive protein (CRP). These elevated CRP concentrations are 
correlated with weight loss, hypermetabolism, anorexia and decreased muscle volume and 
function, known as cancer cachexia. The precise mechanism is still unclear.27-29 In general, 
cancer patients lose weight due to a combination of inadequate food intake and changed 
metabolism, depending on the tumor location, stage, and treatment.
Malnutrition in head and neck cancer patients
Patients with head and neck cancer are specifically at risk for malnutrition. Symptoms such 
as dysphagia, mastication problems, mucositis, xerostomia, changed and/or decreased 
smell and taste, nausea, and trismus due to tumor location and/or treatment side effects are 
frequently seen. These symptoms increase the risk of developing malnutrition.30 The incidence 
of malnutrition in patients with head and neck cancer is 30–57%.31-33 
The incidence is the highest in patients with malignant tumors of the pharynx and oral cavity.34,35 
Patients with stage III/IV tumors have more weight loss than patients with stage I/II tumors.34,36 
Little is known about the presence of unintended weight loss/malnutrition and energy intake 
from diagnosis until rehabilitation and the differences between treatment strategies. This is of 
special interest, because cancer therapies have changed over the last decade, and patients 
at risk for malnutrition should be identified in order to offer optimal nutritional intervention to 
decrease malnutrition. 
Quality of life and malnutrition in head and neck cancer patients
Health-related quality of life (QoL) is a multi-dimensional concept which comprises physical and 
psychological functioning, social interaction, and disease- and treatment-related symptoms.37 
QoL is increasingly being recognized as an important issue in oncology, especially since 
11
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cancer, in general, is becoming a more chronic disease. In addition to traditional clinical 
outcomes, such as tumor response and survival, health-related QoL is a respectable outcome 
measurement in clinical research, representing the patient’s perspective.38 QoL in head 
and neck cancer patients is characterized by a significant decrease in physical functioning, 
increased fatigue and a decrease in appetite. Also disease specific QoL symptoms are 
reduced, from diagnosis till 6 months after treatment and thereafter like trismus, dry mouth, 
sticky saliva, altered taste and/or smell, less (enjoyment in) social eating, and difficulty in 
swallowing.39-41 There is a negative relationship between unintended weight loss and QoL.42,43 
Patients who develop ≥10% weight loss after treatment score lower on items such as role 
functioning, fatigue, loss of appetite, global QoL, sticky saliva, and swallowing, at diagnosis.44 
As such, QoL assessment could identify patients at risk of severe weight loss during and 
after treatment. Knowledge of the relationship between malnutrition and QoL functional and 
symptoms scores before, during and after treatment could help to guide the direction of 
malnutrition prevention and management. 
Nutritional intervention
Over the last decade, clinical research has shown that unintended weight loss and malnutrition 
in head and neck cancer patients have a negative impact on treatment outcomes. There 
are associations with decreased treatment tolerance, increased postoperative complications, 
higher mortality and morbidity rates, shorter failure-free survival and poorer QoL.32,43,45-47 
Nutritional intervention in head and neck cancer patients has been proven to be beneficial to 
prevent unintended weight loss.48-50 Periods of tube feeding (nasogastric or gastrostomy tubes), 
use of oral nutritional supplements and/or food modification are necessary to ensure nutrient 
intake in order to maintain or improve nutritional status.51 Despite the recognized importance 
of nutritional care, scientific data on the benefits of dietary counseling in maintaining stable 
weight and decreasing malnutrition are still scarce. A critical view on the effect of dietary 
counseling in head and neck cancer patients is lacking, but would be of great interest in 
common practice, to offer the optimal nutritional support. 
Food intake and malnutrition in long-term survivors
Chemoradiotherapy is the current standard of care for advanced tumors, but is associated 
with significant early side effects, including mucositis, radiation dermatitis, xerostomia and 
dysphagia12,17, while dysphagia, xerostomia, osteoradionecrosis, trismus and oesophageal 
strictures are known late side effects.52,53 Independent risk factors for severe late toxicity are 
older age, advanced tumor stage, and larynx or hypopharynx tumors.54 Dysphagia appears 
to be one of the most important late complications of chemoradiation that impacts nutritional 
intake.18,55,56 Regarding nutrition, the reported incidence of tube feeding (mostly by means of 
gastrostomy tubes) more than 1 year after chemoradiation varies between 6 and 31%.57-59 
After therapy, tube feeding is a strong negative predictor of QoL.60,61 Reports on long-term 
weight loss/malnutrition and nutritional intake after head and neck cancer treatment are 
scarce but necessary to fully understand the impact of these intensive therapies. 
12
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Nutrition and dysphagia
In current practice, individual dietary counseling is standard in order to optimize or maintain 
nutritional status.62,63 Tube feeding via nasogastric and gastrostomy tubes (30–70%), energy 
drinks (30–50%), and modified foods (30–60%) are frequently necessary in head and neck 
cancer patients to ensure optimal nutritional intake during treatment and rehabilitation.64-66 
These alternative means of nutritional intake have an enormous impact on daily life experiences, 
such as decreased enjoyment in eating, increased eating time and messiness, inability to eat 
in public, and special food preparation, overall resulting in decreased QoL.67,68 Dysphagia is 
significantly related to malnutrition in the period after treatment.69 and is obviously one of the 
most severe and determining factors, besides mucositis, pain, and xerostomia, in alternative 
food intake and decreased QoL for stage II–IV head and neck cancer patients treated with 
radiotherapy or chemoradiotherapy.59,66,70 An important focus of today’s progress in head and 
neck cancer patients’ treatment is improving their QoL. From a paramedical multidisciplinary 
point of view, there seems to be an opportunity to improve “normalcy of food intake”. Clinical 
studies indicate that preventive swallowing strategies may be useful in decreasing dysphagia, 
reducing the need for tube feeding, and improving functional oral intake in treated head 
and neck cancer patients.71-74 However, no randomized controlled trials have been carried 
out. Novel strategies are essential to decrease the uncomfortable experiences with regard 
to means of food intake of head and neck cancer patients during and after treatment. The 
dietician might possibly contribute to innovating strategies to improve “normalcy of food 
intake” by warranting nutritional requirements and offering possibilities in food assortment and 
the speech language pathologist by individual swallowing therapy.
Aims and scope of this thesis
The overall aim of the research described in this thesis is to improve nutritional care for head 
and neck cancer patients. 
Dieticians working with head and neck cancer patients need more knowledge on the severity 
of weight loss/malnutrition and tools to better identify patients at risk. Therefore a prospective 
observational study on weight loss, energy intake and quality of life in head and neck cancer 
patients was performed from diagnosis until revalidation. Subsequently, the lack of evidence 
on the added value of individual dietary counseling above standard nutritional care led to a 
new prospective cohort study on the effect of individual dietary counseling on weight loss and 
malnutrition.
After analysis of the acute and long term QoL issues we found that dysphagia was one of 
the most restrictive symptoms which limited (perception of) food intake and caused weight 
loss/malnutrition. In the light of this we looked for a novel paramedical intervention that could 
address this problem. A randomized controlled trial was undertaken in order to investigate 
whether a multidisciplinary approach with individually dietary counseling and individual 
swallowing therapy could improve restrictions in food intake. 
This thesis incorporates a total of six successive studies based on progressive understanding 
of malnutrition and nutritional related problems in head and neck cancer patients with the aim 
to improve nutritional care for head and neck cancer patients.
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Chapter 2 describes a prospective observational study on the onset and extent of weight 
loss and energy intake in patients with head and neck cancer undergoing different treatment 
to identify the patients at risk. This study describes weight change and energy intake in time, 
from baseline until six months after treatment to determine critical moments of weight loss and 
energy intake. 
Chapter 3 evaluates the relation between malnutrition (≥10% unintended weight loss within 6 
months) and specific QoL parameters during diagnosis, treatment, and rehabilitation in head 
and neck cancer patients.  
Chapter 4 provides a descriptive analysis of QoL issues for the different treatment strategies, 
one month after treatment, to improve quality of care. A reflection of these QoL issues at this 
time point provides a start point to determine the content and intensity of supportive care 
follow-up. 
Chapter 5 reports on the results of a prospective clinical cohort study on the value of dietary 
counseling. This study compared individual dietary counseling by a dietitian against standard 
nutritional care by a nurse on weight loss, body mass index and malnutrition from start of 
radiotherapy until two months after treatment. 
Chapter 6 describes a cross-sectional study on nutritional status, food intake, and dysphagia 
in head and neck cancer survivors treated by chemoradiotherapy with the aim to understand 
the long term nutritional consequences of chemoradiotherapy. 
Chapter 7 describes a randomized controlled trail of combined individual dietary counseling 
and individual swallowing therapy versus usual individual dietary counseling. This study 
was performed in stage II-IV head and neck cancer patients treated with (adjuvant) (chemo)
radiation with the aim to investigate if this combined therapy can improve `normal food intake` 
and decrease dysphagia, malnutrition and improve QoL. 
Chapter 8 provides the summary, general discussion and future perspectives. 
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Abstract 
Background & aims
Patients with head and neck carcinomas often loose a significant percentage of weight, which 
correlates with the complications rate. Only limited information is available on the moment and 
extent of weight loss and energy intake in time and the relation with type of treatment. The 
aim of this study was to describe the moment and extent of weight loss and nutritional energy 
intake in patients with tumors in oral cavity, oropharynx and hypopharynx during diagnosis, 
treatment and revalidation. 
Methods
An observational, prospective study on weight changes and nutritional intake in these patients 
was carried out during diagnosis, treatment and revalidation in relation to the type of treatment. 
Results 
Forty-seven patients successfully completed the study. A significant difference in mean 
bodyweight was found for patients treated by radiotherapy during treatment (-3.3 kg, p=0.01) 
and the early revalidation period (-3.4 kg, p=0.01) and for patients treated with surgery during 
diagnoses (-1.5 kg, p=0,001) and early revalidation period (1.6 kg, p=0.02). 
Overall patients lowered their energy intake by 122 kcal/day followed by a significant increase 
in energy intake during revalidation 326 kcal/day (p=0.04). 
Conclusions
The radiotherapy and the concomitant radio-chemotherapy group lost most body weight 
during treatment and early revalidation. All treatment groups experienced a decrease in 
energy intake during treatment followed by a significant increase during revalidation. 
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Introduction
Squamous cell carcinoma (SCC) in the upper digestive tract is the fourth most common 
cancer type among men in the European community, after cancer of the lung, colorectal and 
prostate. Woman in the European community have a lower incidence compared to men. The 
overall annual standardized incidence rate in the European community has been estimated at 
26.0 per 100.000 in men and 3.1 per 100.000 in woman.1 Tobacco and alcohol consumption 
are major risk factors. In the Netherlands, the total number of head and neck SCC amounted 
to 2400 and 2300 in the years 2001 and 2002 respectively.2
The most common treatment modalities for head and neck cancer patients are surgery, 
radiotherapy, chemotherapy or a combination of these treatments. Despite new techniques in 
treatment, the overall survival rate of this group of patients has not improved for the last two 
decades.3 Weight loss has been implicated as an important prognostic indicator of malnutrition 
in most of the cancers in the Western world.4 Accordingly the progress and outcome of 
treatment in terms of minimizing weight loss, deterioration in nutritional status, global quality 
of life and physical function is due to nutritional status before, during and after treatment.4-10 
Malnutrition, specified as loss of weight ≥5% in 1 month and/or ≥10 % in 6 months, is a 
common problem in head and neck SCC and is present in 30-50% of these patients.11,12 
Patients with SCC in the oral cavity, oropharynx and hypopharynx (OOH) are specifically at 
risk due to nutritional problems like pain, nausea, dry mouth, ageusia, hyposmia and trimus 
induced by tumor location and/ or treatment side effects. Besides the use of tobacco and 
alcohol these patients have less healthy food habits, which predispose for malnutrition.13 
Only limited information is available on the moment and extent of weight change and energy 
intake in relation to the type of treatment in the interval of time of diagnosis, treatment and 
revalidation in patients with OOH. This information is important to decide the optimal moment 
and sort of nutritional intervention. 
Therefore, it was the aim of this study to describe the moment and extent of weight loss and 
nutritional energy intake in patients with tumors in oral cavity, oropharynx and hypopharynx 
during diagnosis, treatment and revalidation in relation to the type of treatment .
Methods and Material
Study population
An observational, prospective study on weight change and nutritional intake in patients with 
SCC of the OOH carcinomas was carried out during diagnoses, treatment and revalidation in 
the Radboud University Nijmegen Medical Centre (RUNMC).
The study was approved by the Committee on Research Involving Human Subjects of the 
RUNMC. All participants signed an informed consent.
Admission criteria included age ≥18 years, primary tumour stage II-IV (UICC TNM-tumor 
classification) in oral cavity, oropharynx, hypopharynx and primary curative treatment 
intentions.14  Patients were treated by different treatment methods depending on stage, 
location and general health conditions: surgery, radiotherapy, combined surgery-radiotherapy 
and concomitant radio-chemotherapy.
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Table 1 Characteristics at baseline of the study subjects and the excluded patients. 
Variabel Total included (n=47) Total drop-outs (n=21)
Age (years) 60.0±9.0a 58±11.7a
Height (m) 1.72±0.09a 1.72±0.09a
Weight (kg) 69.9±14.0a 74.6±16.7a
Tumour stage (n)
T2 29 8
T3 12 7
T4 6 6
Tumor Location (n)
Oral cavity 24 12
Oropharynx 18 7
    Hypopharynx 5 2
Mode of treatment (n) 
Radiotherapy 19 6
Surgery 15 4
Chemotherapy/Radiotherapy 3 7
Surgery/Radiotherapy 10 4
Body mass index (kg/m2) (n)
<18.5 6 3
18.5 – 25.0 26 11
>25.0 15 7
Age groups (years)
30-60 25 14
>60 22 7
Baseline weight status (kg)
Stable weight 34 12
Weight loss 5-10% 13 9
T2 = tumour larger than 2 centimetres but smaller than 4 centimetres and has not spread to lymph nodes.
T3 = tumour larger than 4 centimetres or any size and spread to one of the lymph nodes. 
T4 = tumour of any size but invades adjacent structures. 
BMI (kg/m2): <18.5=Underweight; 18.5-25.0=Healthy weight; >25.0=Overweight (WHO).
a = Mean±Standard deviation.
Figure 1. Study design: Weight (1-6) and energy intake (FFQ1-FFQ3) measurements during diagnosis, treatment 
and revalidation. ΔW= time period between measurements, d=mean days between screening.
Diagnoses Treatment
Early 
revalidation
Late revalidation
1         ΔW1. 21d         2         ΔW2. 37d         3   4          ΔW3. 80d        5                        ΔW4. 105d                      6
                             ΔWDT 58d                                                                   ΔWR 185d
Weight
Energy intake
Diagnoses Treatment
Early 
revalidation
Late revalidation
FFQ1           FFQ2            FFQ3
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Weight change and energy intake were registered during the different phases. The time 
schedule of each treatment was different so measurements took place during the specific 
phases of diagnosis, treatment and revalidation for each therapy (Fig. 1). 
Usual medical and nutritional care was provided. The standard procedure for dietetic 
intervention was maintained. Weight loss and oral supplementation and or tube feeding in 
patients receiving radiotherapy were evaluated by a nurse of the radiation department.
Measurements on age, sex, length and usual weight were taken at the first visit. Height was 
measured with a Seca-scale in meters (two decimals). Patients were asked to recall their 
usual weight at their first visit in kilograms. 
Nutritional assessment 
Weight loss of ≥5% in one month and/or ≥10 % in six months is a well-accepted criterion 
for malnutrition in head and neck cancer patients.4,6,8,11 Therefore, change in body weight 
has been assessed each visit on a calibrated scale (one decimal Seca-scale) while wearing 
lightweight clothing without shoes. All these measurements were taken six times on defined 
intervals shown as ΔW for each treatment process (Fig. 1). 
Energy intake
Nutritional intake was measured three times by a trained dietician: at the first visit, the end 
of treatment and 6 months after treatment by a Food Frequency Questionnaire (FFQ) which 
assesses nutritional intake over the previous month.15 Questions on food consistency were 
added on account of nutritional problems of these patients. Food consumption was measured 
by standard household portion sizes. Food items were coded according to the NeVo 2001, 
The Netherlands.16 Food calculation software was used to calculate nutritional energy intake 
in kcal per day (Vodisys 1.3 Medical Software Infacom IT Consultants b.v.). Changes in 
energy intake over time are defined as ΔWDT (during diagnoses and treatment) and ΔWR 
(during revalidation) (Fig. 1). Energy intake was also calculated in kcal per kg actual body 
weight and compared with energy requirements according to theoretical data (30-40 kcal per 
kg body weight a day). 
Statistical Analyses
The changes in body weight (kg) and energy intake (kcal/day) were expressed as mean ± 
SD. The distribution of variables was evaluated by a Kolmogorov-Smirnov test. The changes 
in energy intake (kcal/day) and body weight (kg) were compared using the Wilcoxon signed 
rank test. 
The relation between changes in energy intake (kcal/day) and body weight change was carried 
out with the Spearman rank correlation coefficient. Difference in weight loss under the types 
of treatment was performed with the Friedman test. Statistical tests were considered to be 
significant at a two-sided p<0.05. Data analyses were carried out with the Statistical Package 
for Social Sciences (SPSS) version 12.1 (SPSS Corporation, Chicago, IL, USA).
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Results
Between May 2002 and May 2004, 47 of 68 patients with SCCOOH met the criteria and 
successfully completed the study, with a male-female ratio of 28:19 and a mean age of 60 
years (30-83). All patients received their tumour treatment at RUNMC. Twenty-one subjects 
finally were excluded from the study (nine dropped out, 12 died during the study). Nine patients 
dropped out because they were too ill to continue the study (n=6), two patients did not show 
up anymore, one patient stopped participation in the study because he had other things on his 
mind. Twelve patients died due to the tumor or the tumor related side effects. Charisteristics 
of the dropped out patients are shown in table 1. At baseline characteristics of the study 
population and the patients who dropped out are not statistically different. (χ²r=8.3, p=0.51) 
Based on treatment strategy patients were classified in four groups: radiotherapy (n=19), 
surgery (n=15), concomitant radio-chemotherapy (n=3) and combined surgery radiotherapy 
(n=10). At baseline, patients had a mean bodyweight of 69.9 kg (41.2 -116 kg). Among them, 
26 patients (55.3 %) started treatment having a body mass index (BMI) in the range of 18.5 to 
25 kg/m2 (WHO), which is the recommended BMI range for a healthy person. Based on their 
self-reported usual weight, 13 patients (27.7%) had lost 5-10% of their body weight in a period 
of one to 6 months prior to their first visit at the clinic (Table 1).
Weight change
In general, patients suffered significant weight loss during treatment (ΔW2: -2.3 kg ± 4.0, 
p=0.001) which continued till revalidation (ΔWR: -2.2 kg ± 5.5, p=0.07).
Treated by surgery alone patients lost significant body weight (ΔW1: -1.5kg ± 2.0 p=0.01) 
during diagnosis followed by weight gain after surgery throughout the early revalidation period 
(ΔW3: 1.6 kg ± 3.5, p=0.02) (Table 2, Figs. 2 and 3). A significant difference in mean body 
weight was found for the patients treated by radiotherapy during treatment and the early 
revalidation period (ΔW2: -3.3 kg ± 3.0 and ΔW3: -3.4 kg ± 2.9, p=0.01). Patients treated 
by a combination of surgery and radiotherapy showed a decline in body weight in the early 
revalidation period (ΔW3: -3.6 kg± 6.2) 
A distinct pattern of change in body weight was found for patients treated by concomitant 
chemo- radiotherapy. A steep decline in body weight was found during treatment (ΔW2:-10.5 
kg ± 6.0) followed by a body weight that was more stable in the early revalidation period (ΔW3: 
-1.0 kg ± 5.6). Body weight decreased again in the late revalidation period (ΔW4:-6.7 kg ± 
7.9). (Table 2, Figs. 2 and 3)
Comparisons of changes in body weight (kg) over time between the treatment groups revealed 
that during diagnosis (ΔW1), the patients treated by surgery showed a significant difference 
compared to other treatment methods. Body weight decreased during treatment for patients 
in all methods of treatment (ΔW2, p=0.001) and in the early recovery period (ΔW3, p=0.03).
A significant difference in weight loss under the different types of treatment (χ²r=10.8, 
p=0.00013) was found.
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Table 2 Mean (SD) weight during diagnosis, treatment and revalidation. 
Mean weight per 
measurement
Total
(n=47)
Radiotherapy
(n=19)
Surgery
(n=15)
Chemo/Rad
(n=3)
Sur/Rad
(n=10)
Weight 1 69.9±13.6 69.6±14.8 67.2±9.5 77.3±8.4 72.5±17.7
Weight 2 69.6±14.2 69.4±14.9 65.7±10.6 79.3±5.4 72.9±18.4
Weight 3 67.3±13.1 66.1±13.1 65.2±9.7 68.9±11.2 72.3±18.1
Weight 4 66.1±11.5 64.0±11.9 66.0±10.4 69.3±4.6 69.4±14.0
Weight 5 65.6±11.7 62.7±12.3 66.8±11.2 67.8±8.3 68.4±12.7
Weight 6 65.1±12.1 62.3±11.8 70.0±10.7 61.1±7.7 69.1±15.2
Figure 2. Mean (SD) weight change in kg between screening moments: during diagnoses treatment and 
revalidation by treatment therapy.
Figure 3. Mean (SD) weight change in kg during diagnoses treatment and revalidation by treatment therapy in 
time.
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Changes in energy intake 
Energy intake (kcal) and energy intake in kcal per kg body weight were measured (Table 3 and 
4). The overall change in energy intake decreased for the whole group from baseline through 
treatment (ΔWDT: 122 kcal/day ± 850), followed by a significant increase in energy intake 
(ΔWR: 326 kcal/day ± 819, p=0.04) during revalidation. Patients treated by radiotherapy 
decreased their energy intake from baseline throughout treatment (ΔWDT: 267 kcal/day ± 
864). Thereafter they had a significant increase in energy intake throughout the revalidation 
period (ΔWR: 498 kcal/day ± 835, p=0.03). The patients with concomitant radio-chemotherapy 
had a decreased energy intake from baseline throughout treatment (ΔWDT: 1234 kcal/day ± 
412). In the revalidation period they had an increase of energy intake amounting (ΔWR: 1141 
kcal/day ± 1852). In the other two groups more modest changes were seen. Patients treated 
with surgery hardly changed their energy intake all the way through. The patients treated 
by surgery and radiotherapy had a slight increase in energy intake from baseline up to the 
treatment period (ΔWDT: 308 kcal/day ± 812) followed by a small fall in energy intake in the 
revalidation period (ΔWR: 31 kcal/day ± 576). (Fig. 4)
Changes in energy intake (kcal) per kg body weight were measured between the different 
screening moments for each type of treatment (Table 4). For all types of treatment energy 
intake in kcal per kg body weight was between the 30-40 kcal per kg body weight. Except for 
the concomitant radio-chemotherapy group during the treatment period the energy intake was 
19 kcal/kg body weights. 
The relationship between mean change in energy intake and mean weight 
The correlation between changes in energy intake and bodyweight were analysed using 
Spearman’s correlation. For all patients, a positive significant correlation between changes in 
energy intake (kcal/day) and bodyweight (kg) from baseline through treatment ΔWDT (rs=0.39, 
p=0.01). During the revalidation period no correlation was found anymore ΔWR (rs=-0.29) 
between the change in energy intake and body weight. In this period, weight declined despite 
an increase in energy intake. 
Table 3 Mean (SD) energy intake in kcal during diagnoses. treatment and revalidation for each type of treatment.
Energy intake per 
measurement (kcal)
Total
(n=47)
Radiotherapy
(n=19)
Surgery
(n=15)
Chemo/Rad
(n=3)
Sur/Rad
(n=10)
FFQ1 2199±721   2347±773  1891±676  2525±977   2280±543
FFQ2 2077±600 2080±430 1889±689 1292±565 2587±328
FFQ3 2399±879 2578±901 2060±780 2433±2022 2556±430
Table 4 Energy in kcal/kg bodyweight (SD) for each treatment modality during diagnoses, treatment and revalidation.
Energy intake (kcal) 
per kg bodyweight 
per measurement
Total
(n=47)
Radiotherapy
(n=19)
Surgery
(n=15)
Chemo/Rad
(n=3)
Sur/Rad
(n=10)
FFQ 1/Weight 1 32±11 35±12 28±10 33±13 33±10
FFQ 2/Weight 3 32±11 33±11 29±11 19±8 37±9
FFQ 3/Weight 6 38±16 43±18 31±11 37±29 39±11
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Discussion
It is well known that patients with SCCOOH often loose a significant percentage of weight, 
which correlates with the prognoses of the patients in time.4-10
Only limited information is available on the moment and extent of malnutrition and energy 
intake in time and the relation with treatment strategy to determine where and when intensive 
nutritional intervention is needed. This prospective observational study analysed the change 
in body weight (kg)/malnutrition and energy intake (kcal/day) during diagnosis, treatment and 
revalidation for SCCOOH patients who undergone different treatment modalities. The pattern 
of change in bodyweight/malnutrition and energy intake differed among sub-groups. 
Not only treatment modality may influence energy intake and weight changes. However 
parameters as tumor stage, tumor location, baseline weight status, baseline BMI, age and 
gender showed no significant difference. 
A significant weight loss was found for the entire group during treatment and the early 
revalidation period. Specified for each type of treatment, a significant loss of body weight during 
diagnoses was only found in the surgery group with the exception that this group showed an 
increase in body weight during revalidation. A significant difference in mean bodyweight was 
found for patients treated by radiotherapy during treatment and early revalidation period. Lees8 
found during radiotherapy –6,5 kg weight loss in patients with larynxcarcinoma. Beaver et 
al.9 also found significant weight loss in patients with oral cavity/oropharynxcarcinoma during 
radiotherapy. A distinct pattern of change in body weight was found for the patients treated by 
Figure 4. The mean (SD) change in energy intake during diagnoses, treatment and revalidation by type of 
treatment 
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concomitant chemo-radiotherapy. During treatment, all patients showed a decrease in body 
weight, this was faster, not significant, for the three patients treated with concomitant chemo-
radiotherapy. In this limited group of patients, all patients started treatment with advanced 
tumour stage, which made them more vulnerable for weight loss.
Almost all treatment groups experienced a decrease in energy intake during treatment 
followed by an significant increase in the revalidation period. More pronounced negative 
changes in energy intake from baseline through treatment were found for the subgroups 
of patients treated by radiotherapy and the concomitant radio-chemotherapy followed by a 
significant increase for the radiotherapy patients and for the concomitant radio-chemotherapy 
group during revalidation.
Consistent with a review study by Tschudi et al.17 on patients who had carcinoma of oropharynx, 
the group of patients who were treated by surgery alone or a combination of surgery and 
radiotherapy did not decrease their energy intake after initiation of treatment. 
The increase in energy intake in the revalidation period did not correspond with the change 
in body weight. Although the energy intake increased during the late revalidation period, a 
decline in body weight was found for patients treated with radiotherapy and concomitant 
radio-chemotherapy. Kenway et al.18 in their study in Nasopharynx cancer patients treated 
by radiotherapy found progressive weight loss and a significant increased total energy 
expenditure between the end of treatment and during revalidation. Bosaeus et al.19 in their 
study on unselected cancer patients found that progressive weight loss was significantly 
related to elevated resting energy expenditure and not with energy intake. 
Although the group of patients in this study is limited, these findings imply a negative energy 
balance after treatment. Metabolic dysbalance may contribute to progressive weight loss 
due to altered responses on body functions. Although nutrition supply is important in this 
period also in relation to complications and quality of live, its supply might be of less benefit 
to maintain stable weight change due to metabolic dysfunction? Further research on this is 
necessary. 
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Summary 
The objective of this observational prospective study in patients with squamous cell carcinoma 
(SCC) of the oral, oropharyngeal and hypopharyngeal cavity was to look into the relation 
between malnutrition (≥10% unintended weight loss within 6 months) and specific quality of 
life (QoL) parameters logitudinally.
Bodyweight and QoL were monitored in 47 patients with SCC at diagnosis, end of treatment 
and six months after treatment. EORTC QoLQ-C30 and H&N 35 questionnaires were used 
to assess QoL.
Significant lower scores on the global QoL during treatment (p=0.01) and revalidation (p=0.02) 
were found for patients who had lost ≥10% compared to patients with <10% loss of weight 
within 6 month. Patients with radiotherapy and a treatment modality of radiotherapy with 
surgery or chemotherapy kept their unintended weight loss until the end of treatment.
Patients with head and neck cancer treated with radiotherapy are specifically susceptible 
to malnutrition during treatment with no improvement in body weight or QoL. Professional 
preventive nutritional support is therefore already required on diagnoses.
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Introduction
Patients with squamous cell carcinoma (SCC) of the head and neck area are particularly at 
risk of developing malnutrition, due to the location of the tumour and their treatment. The 
incidence of malnutrition is high and affects 30-50% patients with a large tumour (T2-4) located 
in the oropharynx and hypopharynx are particularly susceptible.1-4 Unintended weight loss of 
more ≥10% in six months or ≥5% in one month is related to risk of malnutrition.3-5
In addition to the traditional clinical outcomes in tumour response and survival, health related 
quality of life (QoL) has been recognized to be important in clinical research and practice.6-17 
Treatment of head and neck cancer patients should therefore not only aim at the improvement 
of clinical outcome but also maintain or improve QoL.18-19
The QoL depends on physical and psychological well-being and both may influence or be 
affected by nutritional status.17 The relation between unintended weight loss and QoL in 
cancer patients in general and patients with head and neck cancer in particular has been 
studied prospectively. These studies suggest a relation between unintended weight loss and 
impaired QoL from diagnoses until and/or during treatment/revalidation.8,10,12, 14,16,19,20
A logical conclusion would be that unintended weight loss and a subsequent decline in QoL 
may be prevented with adequate nutritional support.17, 21, 22
QoL is an overall expression made up of various parameters. If the QoL score or a certain 
profile of parameters could show a relation with or predict the onset of unintended weight 
loss it would be beneficial to initiate adequate nutritional intervention. It is unknown which 
parameters in head and neck oncology patients are affected by unintended weight loss and 
a subsequent decline in overall QoL especially before diagnoses until the end of treatment 
and six months after treatment. Clarification of this subject is important to support guidelines 
for nutritional support in Head and Neck oncology patients. Therefore an observational, 
prospective study in patients with SCC of the oral, oropharyngeal and hypopharyngeal cavity 
to look into the relation between unintended weight loss and QoL at diagnosis, treatment and 
revalidation was set up. In addition, the relationship between other variables as age, gender, 
tumour stage, treatment, and QoL were evaluated.
Patients and Methods
Design 
This observational, prospective non-randomized study was carried out between May 2002 
and May 2004. Patients with primary untreated head and neck cancer and without other 
malignancies in their history were asked to take part.
Medical treatment i.e. surgery and/or radiotherapy and/or chemotherapy was in accordance 
with the guidelines of the Dutch Cooperative Working Group for Head and Neck Oncology.23 
Nutritional support during the study was in accordance with the common clinical practice at the 
RUNMC, which implies no structural professional nutritional support by a dietician to prevent 
weight loss was given. Prior to diagnoses (baseline) none of the patients had any professional 
nutritional advise from a dietician.24 Advise by a dietician is individual tailored while nutritional 
advise by a trained nurse is concentrated on the use of energy enriched drink formulas. 
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Data collected during the first visit to the out-patient clinic (baseline), the end of treatment 
(treatment) and six months after the final treatment (revalidation) were used to assess the 
relation between unintended weight loss and QoL. At baseline patient characteristics such as 
demographic data (age, gender), tumour stage and location, treatment modality, usual healthy 
body weight (kg), actual body weight (kg) and height (m) were registered. Actual body weight 
was registered again during treatment and revalidation. The QoL questionnaires from the 
European Organisation for Research and Treatment of Cancer (EORTC) EORTC QoLQ-C30 
and EORTC QoLQ–H&N35 have been completed three times. All data were collected when 
patients visited the out-patient clinic and on admittance (Fig. 1). 
The study was approved by the Committee on Research Involving Human Subjects of the 
Radboud University Nijmegen Medical Centre (RUNMC). 
Patients 
All incoming patients with SCC of the oral cavity, oropharynx, hypopharynx referred to the 
out patient clinic were considered eligible to enter the study. Inclusion criteria were age ≥18 
years, treatment with curative intention and primary tumour stage II-IV (UICC TNM-tumour 
classification).25 This group of patients is most at risk for malnutrition.
Patients with major co-morbidity (ASA III-IV) or a history of other malignancies were excluded 
to prevent possible confounding. In all cases treatment was completed within three months 
after diagnosis. All participants gave their written informed consent. Patients were excluded if 
treatment was not carried out at the RUNMC or they were receiving treatment with palliative 
intent. This group serves as a specific model for patients with a high risk on unintended weight 
loss. 
Unintended weight loss/Malnutrition 
Unintended weight loss of 10% or more within the previous 6 months indicates malnutrition 
and correlates with clinical outcome.3,4,5 In this study the afore mentioned definition of 
malnutrition was used. Unintended weight loss was considered to be the outcome of the 
tumour or individual oncological treatment. The periods to establish unintended weight loss 
were defined as 6 months before diagnosis (baseline), 6 months before the end of treatment 
Diagnosis Treatment Revalidation
0      six months        1 three weeks    six weeks         2                    six months               3
0: Self-reported: Usual healthy body weight
1: Measered: Actual body weight at baseline + QoL (Baseline)
2: Measered: Actual body weight at the end of treatment + QoL (Treatment)
3: Measered: Actual body weight six months after treatment + QoL (Revalidation) 
Figure 1 Study design: Weight in kg (0-3) and QoL (EORTC QoLQ-C30, QoLQ-H&N35) (1-3) 
measurements during pre-diagnosis, diagnosis, end of treatment and six months after treatment.
six months
Pre-diagnosis
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(treatment) and 6 months after treatment (revalidation) (Fig.1). At baseline patients were 
asked about their usual body weight during the previous years when they were supposed to 
be free of disease and the possible weight change within 6 months prior to their first visit to the 
out-patient clinic. Weight was checked in the records of the general practitioner file.
Body weight during diagnosis, treatment and revalidation was assessed on a calibrated scale 
to one decimal point (Seca delta nr 707, Seca, Hamburg, Germany) without shoes, wearing 
lightweight clothes. Height (Seca scale) was measured at two decimal points. 
Health related quality of life 
Health related quality of life was assessed with the questionnaires EORTC QoLQ-C30 and 
EORTC QoLQ –H&N35. The general core questionnaire the EORTC QoLQ-C30 includes five 
functional scales (physical, role, emotional, cognitive, social), three symptom scales (fatigue, 
pain, nausea), a global health QoL scale and six single items assessing additional items. The 
head and neck specific questionnaire EORTC QoLQ –H&N35 includes seven multiple item-
scales such as pain, swallowing, senses, speech, social eating and eleven single items. The 
psychometric properties of these questionnaires in patients with cancer have been tested in 
several studies.7,26
The QoL scores were calculated according the procedure in the EORTC QoLQ-C30 and 
EORTC QoLQ –H&N35 (version 3) scoring manual.27 High scores on a functional scale 
represent a high/healthy level of functioning, while a high score on a symptom scale or item 
indicates a high level of problems.
Statistical analysis 
Only data from patients responding to both questionnaires at baseline, throughout treatment 
were used to compare results over time. Data analyses were performed with the Statistical 
Package for Social Sciences (SPSS) version 12.0.1 (SPSS Inc., Chicago, IL, USA). For 
descriptive purposes two unintended weight loss groups were distinguished: unintended 
weight loss ≥10% and <10% within 6 months. The Mann-Whitney U test was applied for 
comparisons between the two groups.
Stepwise linear regression analyses was used to select the predictors of unintended weight 
loss. A clinically relevant difference in QoL score was defined as a difference of 10 points or more 
over time or between groups.28 All tests were two-tailed and a 5% significance level was used.
Results
Compliance 
Sixty-eight patients who met the inclusion criteria signed the form of consent. Twenty-one 
patients were subsequently excluded either because they died during the study (n=12), were 
too ill to take part (n=6) or their data were incomplete (n=3). Finally 47 patients completed 
the study. Standard descriptive demographic information, tumour stage, location and medical 
treatment are presented in Table 1.
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Unintended weight loss 
Correspondence was found between self reported weight at baseline and measured weight in 
the record of the general practitioner. Sixty eight percent of the patients were found to report 
their unintended weight loss within two kilograms. 
Unintended weight loss of 10% or more was assessed in nine patients entering the study, 
while three patients remained malnourished during treatment and one patient continued to 
be malnourished until the end of revalidation. Thirteen out of 15 patients with radiotherapy or 
a treatment modality with radiotherapy were malnourished. Thirty two percent of the patients 
were malnourished at the end of the treatment (Table 1).
Severe unintended weight loss, 8.5% and 9%, was found in two more patients at the end of 
treatment, but not classified as malnourished since the cut-off point for malnutrition was set at 
over 10% unintended weight loss within 6 months.
Table 1 Demographics and distribution of tumour location, tumour stage, treatment modality, body mass 
index and malnutrition ( ≥10% and <10% weight loss) at baseline, end of treatment and revalidation of 
47 patients.
Characteristics                    Weight loss within 6 month
                   Baseline Treatment Revalidation
Total at
Baseline
≥10% <10% ≥10% <10% ≥10% <10%
Number of patients 68 9 38 15 32 5 42
Mean age years (SD) 59 (10) 63 (9.5) 59 (9.5) 62 (9) 59 (9.5) 63 (7) 60 (10)
Gender
Male 45 6 21 10 17 1 26
 Female 23 3 17 5 15 4 16
Tumour location 
 Oral cavity 36 2 21 4 20 1 23
 Oropharynx 25 5 13 9 9 3 9
 Hypopharynx 7 3 2 2 3 1 4
Tumour stage
   T2 36 3 26 5 24 2 27
   T3 20 3 9 6 6 1 11
   T4 12 3 3 4 2 2 4
Teatment
 Surgery 19 1 14 2 13 0 15
 Radiotherapy 25 5 14 8 11 3 16
 Surgery and 
                 radiotherapy 
14 2 8 3 7 0 10
 Chemotherapy and 
                 radiotherapy
10 1 2 2 1 2 1
Body mass index (kg/m2)
                 <18.5 9 2 4 6 3 4 5
                 18.5-25.0 39 2 25 6 27 0 29
                 >25.0 25 5 9 3 7 1 8
Values represent number of patients unless otherwise stated.
Data of the same patients (n=47) were analyzed during baseline, treatment and revalidation.
BMI (kg/m²): <18.5= underweight; 18.5-25.0=normal range; >25 overweight.33
Baseline: Weight (kg) at baseline minus weight 6 month before entering outpatient clinic
Treatment: Weight (kg) day of last treatment minus weight previous 6 month
Revalidation: Weight (kg) 6 month after last treatment.
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During revalidation patients who had surgery gained weight within a range previous to 
diagnosis, while patients with radiotherapy and patients with a combined treatment kept their 
unintended weight loss until the end of treatment.
At baseline three patients had received professional nutritional support by a dietician. None 
of these patients had been assigned to the more than 10% unintended weight loss group. 
Five patients had professional nutritional support during treatment, while two patients had 
had professional nutritional support at the end of revalidation. Two patients who had received 
professional nutritional support had been classified in the ≥10% unintended weight loss group 
at the end of treatment. At the end of revalidation one patient in the ≥10% weight loss group 
had received professional nutritional support.
QoL and unintended weight loss 
The longitudinal results for the EORTC QoLQ-C30 and –H&N35 scores for patients with 
≥10% of and <10% unintended weight loss within six months during baseline, treatment and 
revalidation are presented in Table 2.
Malnutrition in relation to QoL at baseline
Patients who had ≥10% unintended weight loss in six months before baseline showed lower 
scores on the functional scales for global QoL, physical, role, and emotional functioning. On 
the symptom scales fatigue, pain, insomnia, appetite loss, swallowing, decreased sexuality, 
sticky saliva and coughing proved to be higher and therefore worse in the ≥10% unintended 
weight loss group. The scores were significantly different for cognitive functioning (p=0.05), 
fatigue (p=0.02), dyspnoea (p=0.01) and loss of appetite (p=0.02). Eighteen scores deviated 
by more than 10 points and could be marked as clinically relevant (Table 2).
Malnutrition in relation to QoL at the end of treatment 
During treatment the scores of patients who had lost ≥10% weight had a tendency to decline 
on role and social functioning and were lower compared to the <10% unintended weight loss 
group. Scores on the QoL significantly differed for global QoL (p=0.01), fatigue (p=0.03), pain 
(p=0.04), senses problems (p=0.05), sticky saliva (p=0.01), coughing (p=0.02) and feeling ill 
(p=0.01) during treatment (Table 2). 
Malnutrition in relation to QoL, six months after treatment
Six months after treatment the QoL scores of patients who had lost ≥10% weight were lower 
on physical, role, emotional and cognitive functioning. Symptom scales also scored worse 
than in the <10% unintended weight loss group.
During revalidation the difference between the scores on global QoL (p=0.02), fatigue (p=0.02), 
nausea and vomiting (p=0.02), pain (p=0.01), social eating (p=0.04), dry mouth (p=0.03) and 
sticky saliva (p=0.04) proved to be significant.
The occurrence of malnutrition shows a decline in the global QoL score and is specifically 
prominent in patients treated with radiotherapy. Overall data show a tendency of severe weight 
loss and worse scores on QoL, although not significant for all items in QoL and throughout the 
time span from diagnosis until six month after treatment.
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Table 2 EORTC QOLQ-C30 and QOLQ-H&H35 scores in 47 patients with ≥10% and <10% weight loss 
within 6 month at baseline, during treatment and revalidation
Baseline  Treatment  Revalidation 
Weight loss groups ≥10% <10% ≥10% <10% ≥10% <10%
Number of patients 9 38 15 32 5 42
Score Mean p Mean Mean p Mean Mean p mean
EORTC QOLQ-C30
Global QOL 55 64 41 0.01a 61 38 0.02a 63
Physical functioning 65 a 81 62 70 58 a 77
Role functioning 58 a 76 43 a 55 58 a 71
Emotional functioning 60 a 72 66 73 52 a 78
Cognitive functioning 77 0.05a 87 77 82 70 a 81
Social functioning 83 88 67 a 80 80 80
Fatigue 44 0.02a 29 63 0.03a 45 69 0.02a 34
Nausea and vomiting 19 13 22 16 42 0.02a 5
Pain 46 a 34 50 a 35 54 0.01a 26
Dyspnoea 24 0.01a 11 24 16 17 15
Insomnia 54 a 39 29 33 50 a 30
Appetite loss 38 0.02a 22 49 a 38 58 a 22
Constipation 8 10 13 20 25 a 11
Diarrhoea 8 10 13 10 8 11
Financial difficulties 4 7 16 9 11 11
EORTC QOLQ-HN35
Pain 47 42 56 0.04 a 41 60 a 32
Swallowing 44 a 30 60 a 40 52 a 30
Senses problems 6 15 53 0.05 a 33 37 33
Speech problems 26 20 51 43 28 25
Social eating 25 28 49 a 17 61 0.04 a 23
Social contact 9 8 19 a 41 18 11
Less sexuality 36 a 22 44 a 20 33 29
Teeth 24 a 38 33 a 46 67 a 29
Opening mouth 29 38 53 55 67 a 32
Dry mouth 38 36 71 a 56 100 0.03 a 62
Sticky saliva 50 a 31 89 0.01a 26 75 0.04 a 50
Coughing 38 a 27 47 0.02a 29 42 a 24
Felt ill 29 22 38 0.01 29 42 a 17
Pain killers 100 a 67 80 a 61 67 a 53
Nutritional supplement 63 a 28 53 55 67 a 26
Feeding tube 38 a 8 67 a 13 17 18
Weight loss 50 a 39 87 a 58 67 a 21
Weight gain 13 19 13 19 0 a 37
Values represent mean. Note: A high score on a functional scale represents a high/ healthy level of func-
tioning, but a high score for a symptom scale or item indicates a high level of problems.
a Clinically significant difference (10 point or more)
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QoL and treatment modalities
A clinically significant difference was found between the different treatment modalities. Surgery 
patients scored highest on QoL which indicate a better outcome where as patients treated with 
radiotherapy as single therapy modality score the lowest (Table 3). 
Regression analysis 
A stepwise linear regression analysis /ANOVA was performed to determine whether unintended 
weight loss could be predicted by patient characteristics (age, gender, tumour stage and 
treatment modality) and the QoL scores. The analysis was run with the data at baseline, end 
of treatment and six months later. 
Tumour stage explained the variance (10%) of unintended weight loss during treatment. 
Tumour stage also accounts for 10% of the variance for emotional functioning, appetite loss 
and swallowing at baseline. The former applies for emotional functioning, social functioning 
and the symptom scales pain, swallowing, senses, social eating problems, teeth, opening 
mouth and dry mouth during treatment. Ten percent of the variance of emotional, cognitive 
and social functioning was explained by the tumour stage during revalidation, while treatment 
modality accounted for 10% of the variance for cognitive functioning and fatigue.
Discussion
In this prospective observational study the relation between malnutrition (unintended weight 
loss ≥10% weight loss in 6 months) and QoL parameters in patients with SSC of the oral cavity, 
oropharynx and hypopharynx during diagnosis, treatment and revalidation was explored. 
Correlation between QoL scores and characteristics as unintended weight loss, age, gender, 
tumour stage and treatment modality was also evaluated. 
Nineteen percent of the patients were considered to be malnourished at baseline, which 
corresponds with other studies.3,4,29 More patients (32%) were malnourished at the end of 
treatment. This result is in part similar to the percentage of malnourished patients found in 
studies of Hammerlid et al.12 and Beaver et al.30 
Hammerlid et al. however defined malnutrition as 5% unintended weight loss and used 
anthropometrical criteria. Westin et al.31 found 38% of malnutrition but defines different 
(anthropometric) parameters for this condition than those applied in this study. In all other 
Table 3 Global Qol scores in 47 patients treated with surgery, radiotherapy, surgery with radiotherapy, 
chemotherapy and radiotherapy at baseline, during treatment and revalidation
Treatment modality Surgery     Radiotherapy      Radiotherapya 
Number of patients 15 19 13
EORTC QOLQ-C30
Global QOL score
Mean (SD) Mean (SD) Mean (SD)
Baseline 60 (20) 61 (19) 60 (22)
Treatment 66 (20) b 45 (18) b 56 (22)
Revalidation 68 (20) b 54 (22) b 65 (12)
a Radiotherapy = surgery and radiotherapy (n=10) and chemotherapy and radiotherapy (n=3).
b Clinically significant difference (10 point or more).
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nutritional studies unintended weight loss is mentioned as the most accepted criterion for 
malnutrition.3-5,9
At diagnoses the group with more than 10% weight loss already scored significantly worse 
on cognitive functioning, fatigue, dyspnoea and appetite loss which implies that weight loss 
at diagnoses already has a major impact on important quality of life scores. Thereby, this 
group scored lower on global QoL during treatment and revalidation. The scores for fatigue 
were higher for the group with more than 10% unintended weight loss. This proved significant 
at baseline as well as during treatment and revalidation. Ravasco et al.20 also found this 
in their study for the group with a declined nutritional status according to subjective global 
assessment (SGA).20 Pain also seemed to be significantly worse in the more than 10% weight 
loss group during treatment and revalidation. 
A relation between unintended weight loss and low QoL scores has been shown in several 
studies,9,13,16,21 but patients with less than 10% weight loss scored higher on QoL than the 
similar group in this study. In one study9 the group that lost less weight scored better between 
baseline and treatment on emotional and physical functioning and dyspnoea. During treatment 
and revalidation the better-nourished group had higher scores on global QoL, which is similar 
to the findings in this study. Which is also described in the study in Ravasco et al.20 Contrary 
to a study of Hammerlid et al.12 no correlations between QoL scores and severe unintended 
weight loss was found, however tumour locations were different and tumour stage I was 
included.
This shows that more than 10% of weight loss has a great impact on QoL scores already at 
diagnoses. No further deterioration of malnutrition in this stage is allowed especially when 
treatment has to be started. Also more than 10% weight loss seemed to be significantly worse 
for global quality of life, fatigue and pain. This confirms reducing weight loss from diagnoses 
till six months after treatment is needed. 
Stepwise logistic regression analysis revealed that the tumour stage had a significant influence 
on QoL scores. The influence differed for each phase of treatment but was consequently 
significant for emotional functioning during the entire period (baseline-revalidation) Tumour 
stage was the most important variable in determining the value of cognitive and social 
functioning at the end of treatment and six months thereafter.
Treatment modality also appears to be a significant variable for cognitive functioning and 
fatigue. However, only a small part of the statistical variance in this model could be explained 
by the parameters applied. This suggests that other factors, not accounted for during and in 
this study, are relevant in determining the value of the global QoL score. 
In prospective studies19,32 tumour stage was also found to have the most powerful impact on 
QoL scores. It seems that the development of the disease is most important for the global 
QoL of most patients. Tumour stage can be linked to duration of disease and the number and 
severity of problems that are more common with increased tumour size. The variables age 
and gender were found to have no significant influence in both QoL questionnaires. In the 
study of De Greaff et al.18 age and gender were also found to have minimal influence on the 
QoL scores. The variation in tumour stage explains a significant percentage in the variance of 
the global QoL score after treatment and revalidation, where factors such as coping, cognitive 
orientation and social support may also play a role in determining QoL scores.18 Since QoL is 
such a subjective measure, it is impossible to take all existing influencing factors into account. 
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No structural nutritional support by a dietician to prevent weight loss was given during this 
study.24 As a result of this study the Head and Neck guidelines have been updated. Since the 
end of 2004 all Head and Neck cancer patients in the out-patient clinic and the clinical ward of 
the Radboud University Medical Centre have nutritional support by a dietician.
Malnutrition was defined as unintentional weight loss of 10% or more within the previous 6 
months. To determine the percentage of unintended weight loss at diagnosis and after finishing 
treatment, the self-reported normal healthy body weight of the patients was used. The usual 
healthy body weight was defined as the stable body weight of the patients before the onset of 
the disease. The assumption was made and queried that this body weight had been stable for 
at least 6 months before diagnosis. To confirm this assumption weight has been checked in 
the records of the general practitioner.
A body mass index (BMI) ≤18.5 is a classification for underweight.32 If this classification had 
been taken into account in this study more patients would have been indicated as malnourished. 
Treatment modality largely depends on tumour stage and location. It appears that patients with 
radiotherapy as a single therapy or in combination with surgery or chemotherapy continuously 
scores worst. These patients are at risk of malnutrition during the entire treatment with no 
improvement in body weight or QoL after final revalidation. Data show a tendency of severe 
weight loss and worse scores on QoL. Although a significant correlation between weight loss 
and all items from diagnosis until six month after treatment could not be established in this 
study. It is possible to prevent severe weight loss17 or keep weight loss at a minimum with 
professional nutritional support and therefore positively influences the process of revalidation. 
A better score on QoL gives a better outlook on coping with possible side effects of treatment.
Former implies that professional preventive nutritional support specifically for patients with 
radiotherapy is already required on diagnosis to prevent further unintended weight loss and 
should be maintained throughout the entire procedure at least until six months after treatment.
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Abstract 
Objective 
To investigate the health-related quality of life (HRQoL) and supportive follow-up care needs 
one month post-treatment for patients with advanced-stage (stage III or IV) radiated head and 
neck cancer (HNC) who were treated with curative intent. 
Study design 
An exploratory, descriptive analysis of HRQoL data obtained from three treatment groups: 
conventional radiotherapy (RT, n=21), surgery+radiotherapy (SRT, n=10), and chemoradiation 
(CRT, n=21). 
Setting, subjects and methods
The head and neck oncology centre of an university hospital. Fifty-two patients completed 
the EORTC QLQ-C30 and EORTC QLQ-H&N35 self-report questionnaires one month post-
treatment. Descriptive statistics and clinically relevant differences between the groups were 
analysed. 
Results
HRQoL outcomes between groups differed. Clinically relevant difference was observed in the 
RT and CRT group with respect to dry mouth, coughing, feeling ill, use of pain killers, and the 
use of nutritional supplements. The RT group differed from the other groups with respect to 
pain and swallowing. The CRT group differed from the other groups regarding role functioning. 
Conclusions
HRQoL differs between RT, SRT, and CRT patients one month post-treatment. The RT- and 
CRT-treated patients reported higher impairment than the patients who were treated with SRT. 
Nutritional intake and oral function emphasize the importance of providing supportive care to 
radiated advanced-stage HNC patients throughout the treatment trajectory and the need for 
continuation during the first few post-treatment months. 
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Introduction
Every current treatment for head and neck cancer (HNC) places a burden on the patient, 
and nearly all patients experience a progressive deterioration in health-related quality of life 
(HRQoL) towards the end of treatment.1,2 For most patients, these health-related complications 
largely disappear during the first post-treatment years.3,4 However, if complications remain 
after one year, little—if any—significant improvement can be expected through the 3-year 
follow-up period, particularly among patients who received conventional radiotherapy as part 
of their treatment.1,5 
The choice of treatment for HNC is determined by both the tumour size (stage) and location of 
the tumour, and these factors must be considered when interpreting HRQoL outcome.6 Although 
multimodal treatment can lead to an increased prevalence of HRQoL consequences compared 
to single-modality treatments, the literature contains contradictory reports, particularly with 
respect to long-term differences (i.e., 12 months and longer).4,7-11 HNC patients who are 
treated surgically can experience complications such as wound infection, microvascular 
flap complications, shoulder disability, swallowing and/or chewing difficulties, and aesthetic 
changes.4,12 Radiotherapy can lead to complications such as mucositis, dysphagia and 
xerostomia, trismus and fibrosis.5,13-15 In addition to the aforementioned radiotherapy-related 
complications, chemoradiation-specific complications can include infection, hematopoietic 
suppression, renal failure, pneumonia, the need for tube feeding, and fatigue.8,9,16,17 
To provide on high-quality care and enhance treatment outcomes, it is important to assess 
HRQoL routinely throughout the treatment trajectory, address problems and complications in 
an early stage and discuss the short- and long-term treatment-related health consequences 
with the patient.3,18 Although many studies have investigated HRQoL in HNC patients, 
relatively few studies provide data regarding the immediate post-treatment period; indeed, 
the 3- and 6-month periods are the most commonly reported short-term measurements. 
Therefore, we determined HRQoL at one month post-treatment to add to the short-term data 
and to gain insight into the problems experienced by radiated HNC patients which received 
different treatment. We also use these results to provide a direction for the type and intensity 
of supportive follow-up care within the first weeks to months in the post-treatment period.
Methods
A descriptive exploratory analysis was performed on a subset of data from HNC patients 
(n=160) who participated in a prospective non-randomized trial between November 2007 and 
February 2009 (ClinicalTrials.gov NCT01167179).19 This trial assessed the effects of nurse-
led follow-up consultations on psychosocial adjustment to illness and on health related quality 
of life. A usual care group (n=80), that functioned as a historical control group, was compared 
with an intervention group (n=80) for which nursing consultations were added to the medically 
oriented follow-up schedule. All patients (n=160) had completed the EORTC QLQ-C30 and 
EORTC QLQ-H&N35 questionnaires at the baseline measurement set at 1 month post-
treatment. Until that moment all patients had received usual care during treatment. As from 
one month, the intervention group started with the additional nursing follow-up consultations. 
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Remaining longitudinal measurements were at 6 and 12 months, respectively. Participating 
patients had all been treated at the Head and Neck Centre of the Radboud University Centre for 
Oncology in Nijmegen, the Netherlands. All patients provided a written informed consent, and 
the study was approved by the Medical Ethical Committee of the district Arnhem-Nijmegen, 
and was conducted in accordance with the Declaration of Helsinki (CMO-nr. 2007/113).20,21
Sample
The patient demographic and disease characteristics are presented in Table 1. The sample 
consisted of 52 HNC patients with locoregionally advanced (stage III or IV) cancer who had 
been treated with curative intent using conventional radiotherapy (RT group, n=21), surgery 
followed by radiotherapy (SRT group, n=10), or chemoradiation (CRT group, n=21). The 
treatment that each HNC patient received was in accordance with to the guidelines of the 
national Head and Neck Society.22 
Table 1 Demographics and Disease Characteristics (n=52 patients)
Total Surgery + 
Radiotherapy
Radiotherapy Chemo
radiation
p Valuea
Number 52 10 21 21
Gender 0.27
Male 39 6 15 18
 Female 13 4 6 3
Age, y 0.40
 Mean (Median) 56 (57) 58 (60) 58 (57) 53 (53)
 Range 26 - 82 26 - 82 44 - 75 30 - 75
Cancer site 0.06
Oral cavity 9 7 0 2
Oropharynx 15 0 9 6
Hypopharynx 6 0 2 4
Nasopharynx 4 0 0 4
Larynx 15 2 10 3
Other 3 1 0 2
Stageb 0.48
III 13 1 6 6
IV 39 9 15 15
a Kruskal-Wallis test
b Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours. 7th ed.Geneva, 
Switzerland:UICC; 2011.
Data collection
HRQoL was measured using the European Organisation of Research and Treatment of 
Cancer Quality of Life Questionnaire with the Head & Neck Module (EORTC QLQ-C30 
and QLQ-H&N35).23,24 The EORTC QLQ-C30 and the EORTC QLQ-H&N35 are cancer-
specific, patient-based self-report questionnaires, and the psychometric properties of both 
questionnaires have been tested by several studies.25,26 The core questionnaire is composed 
of five functional scales, a global health status/QoL scale, and nine symptom scales. The 
additional head and neck module (EORTC QLQ-H&N35) contains 18 disease-specific 
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symptom scales. A high score on the functional scales and the global health status/QoL scale 
represents a high functional level, whereas a high score on the symptom scale represents a 
high level of symptoms.24 
Analysis
The mean scores and standard deviations of the EORTC QLQ scales were calculated in 
accordance with the recommended procedures in the scoring manual using SPSS 18.0.24 
Due to the small sample size and non-normal distribution of the data, the differences between 
treatment groups with respect to demographic and disease variables were tested using the 
non-parametric Kruskal-Wallis test. Clinically relevant differences between the groups were 
also calculated, as this adds to the meaningful clinical interpretation of otherwise aggregated 
mean EORTC scores. A difference of >10 points in mean EORTC scores was viewed as 
being clinically relevant.27-29 An EORTC mean score of 50 was used as a threshold to detect 
HRQoL items that indicated worse or better functioning within the groups. A mean score of 
≤50 on the function scales and global health status/QoL or and a score of ≥50 on the symptom 
scales was regarded as a sign of impaired function on a given scale. Because this study was 
exploratory in design and contained a relatively small sample size, multiple statistical testing 
was not considered appropriate and was therefore not performed. 
Results
Our analyses revealed that the treatment groups did not differ significantly with respect to age, 
gender, or stage grouping (Table 1). The average of the patients (39 men and 13 women) was 
56 years (range, 26-82 years). Seventy-five per cent of the patients had a stage IV tumour, 
and the oropharynx and larynx were the two most common tumour locations. Intensity-
modulated radiation therapy (IMRT) was used in the treatment of 34 (65%) patients. Although 
they were not statistically significant (p>0.05), the differences in tumour site between the 
treatment groups can be explained by the fact that the treatment variables were determined 
using established guidelines.22 
Functional scales and global health status/QoL
None of the groups had a mean score of ≤50 on either the EORTC QLQ-C30 functional scales 
or the global health status/QoL scale. With respect to the functional scales, role functioning 
was impaired in all groups, with the CRT group having clinically relevant lower scores (i.e. 
worse functioning) relative to the SRT and RT groups, respectively. Details are presented in 
Table 2.
Symptom scales
With respect to the EORTC QLQ-C30 and H&N35 symptom scales, the SRT group had mean 
scores of 50 points or higher for sticky saliva and weight loss, and the RT and CRT groups 
had mean scores of 50 or higher for dry mouth, sticky saliva, the use of pain killers, the use 
of nutritional supplements, and weight loss. Analyses of the clinically relevant differences 
between the groups revealed that compared to the other groups, the SRT group had higher 
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Table 2 EORTC QLQ-C30 and EORTC QLQ-H&N35 scores and clinically relevant differences between the 
treatment groups at 1 month posttreatment
Surgery+
Radiotherapy
(n=10), Mean 
(SD)
Radiotherapy
(n=21), Mean 
(SD)
Chemo
radiation
(n=21), Mean 
(SD)
SRT
vs.
RT, 
Δa
RT
vs.
CRT, 
Δa
CRT
vs.
SRT, 
Δa
EORTC QLQ-C30 
Functional scalesb
Global health status/
QoL
71 (15) 72 (17) 66 (25)
Physical functioning 80 (14) 83 (18) 74 (29)
Role functioning 69 (22) 75 (28) 57 (36) +18 -12
Emotional 
functioning
81 (25) 81 (20) 83 (21)
Cognitive functioning 83 (15) 85 (19) 83 (17)
Social functioning 83 (28) 84 (21) 79 (23)
Symptom scalesc
Fatigue 33 (30) 32 (26) 44 (30) -12 +11
Nausea/vomiting 8  (9) 28 (36) 19 (31) - 20 +11
Pain 19 (20) 34 (34) 19 (18) - 15 +15
Dyspnoea 17 (18) 6 (18) 15 (24) +11
Insomnia 17 (28) 27 (25) 20 (21)
Appetite loss 22 (27) 29 (40) 44 (30) -15 +22
Constipation 17 (28) 27 (25) 20 (31)
Diarrhoea 6 (14) 8 (15) 6 (13)
Financial difficulties 11 (17) 13 (27) 10 (20)
EORTC H&N35c
Pain 21 (24) 38 (25) 31 (17) -17
Swallowing 25 (25) 45 (33) 28 (26) -20 +17
Senses 33 (24) 41 (32) 36 (20)
Speech 19 (27) 28 (24) 24 (24)
Social eating 33 (36) 34 (26) 32 (27)
Social contact 3 (6) 8 (14) 7 (11)
Sexuality 31 (27) 29 (32) 44 (37) -15 +13
Teeth 28 (33) 17 (32) 12 (20) +11 -16
Opening mouth 44 (50) 27 (33) 37 (38) +17
Dry mouth 39 (25) 63 (36) 63 (30) -24 +24
Sticky saliva 50 (28) 54 (38) 67 (33) -13 +17
Coughing 11 (17) 38 (36) 39 (31) -27 +28
Feeling ill 11 (17) 27 (33) 22 (28) -16 +11
Pain killers 33 (52) 69 (48) 56 (51) -36 +13 +23
Nutritional 
supplements
33 (52) 50 (52) 83 (38) -17 -33 +50
Feeding tube 0 (0) 0 (0) 33 (49) -33 +33
Weight loss 50 (55) 56 (51) 50 (51)
Weight gain 33 (52) 25 (45) 17 (38) -16
Abbreviations: CRT, chemoradiation; QoL, quality of life; RT, radiotherapy; SRT, surgery + radiotherapy
a Δ = clinically relevant difference of >10 points, indicated by bold figures.
b Higher score, better functioning (range 0-100). c Higher score, more symptoms (range 0-100).
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(i.e., worse) scores for problems with teeth, but lower (i.e., better) scores for nausea/vomiting, 
dry mouth, coughing, feeling ill, the use of pain killers, and the use of nutritional supplements. 
The RT group had higher (i.e., worse) scores for pain and swallowing, but no lower (i.e., better) 
scores on any scale compared to the other groups. The CRT group had higher (i.e., worse) 
scores for fatigue, nausea/vomiting, appetite loss, problems with sexuality, sticky saliva, the 
use of pain killers, the use of nutritional supplements, and the use of a feeding tube. 
Discussion
The goals of this study were to gain insight into the HRQoL of irradiated advanced-stage HNC 
patients one month post-treatment and to determine which items should be given particular 
consideration in future supportive care during early rehabilitation. In the published literature, 
few studies have provided data regarding the early post-treatment period; therefore, it is 
difficult to compare our findings directly with the findings of others. Overall, the SRT group 
seemed to experience less of a decrease in HRQoL than the RT and CRT groups. 
Function scales and global health status/QoL
With the exception of role functioning, the groups exhibited no clinically relevant differences 
with respect to their functional scales and global health status/QoL. Role functioning was 
most impaired in the CRT group relative to the other two groups. Several other studies that 
compared different treatment protocols have reported this same finding.17,30,31 With respect to 
our CRT group, this finding could be a function of the severity of symptoms related to various 
aspects of nutritional intake and/or appetite loss and to the fact that one-third of the patients 
remained dependent on tube feeding one month post-treatment (and all but 4 of the patients 
used nutritional supplements). Dependency on tube feeding is known to have a negative 
effect on social activities and role functioning.32
Symptom scales
The clinically relevant differences between the treatment groups regarding the symptom 
scales pointed predominantly toward the scales that are related to nutritional intake (i.e., 
appetite loss, nausea/vomiting, swallowing, tube feeding, the use of nutritional supplements, 
and weight loss) and oral function (i.e., dry mouth, opening mouth, sticky saliva, and problems 
with teeth). In addition, the groups exhibited clinically relevant differences with respect to pain, 
coughing, and fatigue. 
Problems related to nutritional intake
Several studies have reported that problems with respect to nutritional intake, swallowing, 
senses and impaired oral function can persist for well over a year post-treatment.1,21,33-35 
Therefore, the importance of assessing and monitoring these items early seems obvious.36 
Early supportive care—including intensive nutritional counseling by a dietician regarding 
maintaining body weight—led to improved nutritional status, better treatment tolerance, fewer 
hospital admissions, and, consequently improved treatment outcome.37-42 Most nutritional 
guidance programs end within eight weeks of treatment; however, some studies have argued 
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that patients with advanced-stage tumours—particularly patients who are treated using RT 
and CRT—require a longer period of dietary counseling.38,43 This is particularly important for 
patients who remain dependent on tube feeding (one-third of the CRT group in our study). 
Indeed, prolonged tube insertion can be associated with, impaired swallowing and speech 
and, a decrease in overall quality of life.44-46 
In our study, we found clinically relevant negative scores for swallowing in the RT group, with 
a difference of nearly 20 points compared with the other groups. This result has been well-
described in irradiated patients with pharyngeal cancer, and this was the predominant tumour 
site in our RT group.47 On the other hand, pharyngeal cancer was also predominant in the 
CRT group, although the scores in this group for swallowing were similar to the scores in the 
SRT group, which contained no pharyngeal cancer patients. We have no further explanation 
for this finding. However, dysphagia and the associated increased risks of aspiration and 
pneumonia are well-known problems in this patient group.8 Therefore, an assessment of 
dysphagia prior to treatment and subsequent rehabilitation in patients with advanced and/or 
pharyngeal cancer may be an important predictor of chronic dysfunction.48 
The health consequences of problematic nutritional intake in HNC patients have also been 
studied qualitatively, and reports indicate that nutritional symptoms and concerns and fatigue 
can have the greatest impact on the patient’s attempt to achieve a normal life after treatment 
has ended.49 Another study suggested that healthcare professionals who address nutritional 
problems in HNC patients should also talk with patients regarding their experience of the 
(changed) meaning of food following treatment in order to help support the patient’s need to 
cope with changes or losses in this area.50
Problems related to oral function
The SRT group had clinically different scores with respect to problems with their teeth and 
opening their mouths. In this group, in which oral cancer was the predominant tumour site, 
problems with the teeth are an expected outcome, as surgical treatment routinely includes the 
extraction of teeth and extensive dental rehabilitation, including implants.51 The scores are 
consistent with the postoperative discharge scores reported by Lee et al. for HNC patients 
who were treated with surgery alone.52 The inability to bite or chew properly is a potential risk 
factor for the (gradual) deterioration of nutritional status and oral function and can also impact 
both short- and long-term HRQoL.53 The SRT group seemed to carry a high risk, particularly 
in combination with a clinically higher (i.e., worse) score for opening the mouth. Hence, 
nutritional intake and oral function are clear points of attention for this group, and this is also 
confirmed by their high mean scores for sticky saliva and weight loss.
With respect to oral function, the RT and CRT groups had clinically relevant higher (i.e., worse) 
scores for dry mouth and sticky saliva compared with the SRT group. The mean scores for 
these items in both the RT and CRT groups were 10-20 points higher (i.e., worse) than in 
studies that reported three-month data for these same treatment groups.5,17 Although these 
symptoms tend to improve over time, their impact on the patient cannot be neglected, as they 
are predictors of long-term weight loss.54
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Pain and fatigue
Pain scores were highest (i.e., worse) in the RT group compared to the other two groups. 
We currently have no specific explanation for this finding in this treatment group, as pain is a 
known symptom during treatment and during the first post-treatment months in all irradiated 
HNC patients.55 Pain can range from neuropathic pain to mucositis-related pain and other 
treatment-related pain. However, pain has been reported to be an undermanaged item in HNC 
patients, thus having a negative impact on all other HRQoL items; therefore, pain deserves 
to receive adequate professional attention.56 Fatigue was present in all treatment groups, but 
scores were highest (i.e., worse) in the CRT group. Fatigue is most severe during radiation 
treatment and then improves gradually after treatment has ended.57 However, because fatigue 
is often viewed as a general treatment-related side effect, it is perhaps not always addressed 
effectively. Moreover, increased levels of fatigue are tightly correlated with decreased QoL.58 
In summary, these results support our clinical experience that prolonged intensive supportive 
care is warranted for irradiated advanced-stage HNC patients during the early stage of 
rehabilitation. In our setting, the medical routine follow-up schedule consists of twice-monthly 
control visits to a physician in the first year of follow-up. To provide adequate supportive care 
for all irradiated HNC patients during the first few post-treatment months, we recommend that 
patients have frequent contact with the supportive care providers within the multidisciplinary 
head and neck team. This care could well be organized and coordinated within the context 
of nurse-led clinics, encompassing specific counseling of dieticians, dental health care 
professionals, and other supportive care providers.19,43,59 These contacts could be planned 
and guided in accordance with the severity of existing symptoms and problems, together with 
high-intensity contact immediately following treatment. It would be worthwhile to investigate 
whether such an intensified approach guided by symptom assessment can influence the 
general treatment outcome of HNC cancer patients.
When interpreting the results of this study, it is important to acknowledge the study’s limitations. 
The treatment groups in this study were extracted from the cohort of a non-randomized 
prospective trial that was conducted in one hospital only. Consequently, we were unable to 
control how the groups were composed. Therefore, our relatively small sample size warrants 
caution in the generalization of our findings. However, despite this limitation, these results 
provide insight into short-term supportive care issues and differences with respect to various 
modalities for treating irradiated patients with advanced-stage HNC and will be helpful in 
improving supportive care further.
Conclusions
Our results indicate that several HRQoL items necessitate intensive supportive care at 
one month post-treatment for irradiated advanced-stage HNC patients, and this necessity 
is primarily a reflection of aspects regarding nutritional intake and oral function. The CRT 
and RT groups appear to have the highest need for intensive supportive care in the early 
post-treatment months. We argue that supportive care of these advanced-stage patient 
groups should be included in all phases of treatment and—depending on the severity of the 
symptoms—should be extended into the rehabilitation phase. A multidisciplinary head and 
neck team comprised of dieticians, nurses, dental health professionals and physicians is 
essential for incorporating this care into the treatment trajectory.
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Abstract
Clinical research shows that nutritional intervention is necessary to prevent malnutrition 
in head and neck cancer patients undergoing radiotherapy. The objective of the present 
study was to assess the value of individually adjusted counseling by a dietician compared 
to standard nutritional care (SC). A prospective study, conducted between 2005 and 2007, 
compared individual dietary counseling (ICD, optimal energy and protein requirement) to SC 
by an oncology nurse (standard nutritional counseling). Endpoints were weight loss, BMI 
and malnutrition (≥5% weight loss/month) before, during and after the treatment. Thirty-eight 
patients were included evenly distributed over two groups. A significant decrease in weight 
loss was found 2 months after treatment (p=0.03) for IDC compared with SC. Malnutrition 
in patients with IDC decreased over time, while malnutrition increased in patients with SC 
(p=0.02). Therefore, early and intensive individualised dietary counseling by a dietician 
produces clinically relevant effects in terms of decreasing weight loss and malnutrition 
compared with SC in patients with head and neck cancer undergoing radiotherapy.
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Introduction
Malnutrition is a substantial problem in Dutch health care. This applies for more than one in five 
patients.1 In head and neck cancer patients malnutrition, specified as unintended weight loss 
of ≥5% in one month and/or ≥10% in six months, has been reported in 30-50%, particularly in 
those with squamous cell carcinomas in the oropharyngeal and hypopharyngeal areas.2,3 The 
most common treatments for these patients include surgery, radiotherapy, chemotherapy or a 
combination of these.4,5 The risk of nutritional deterioration is increased during actual treatment. 
Radiotherapy and/or chemoradiation induce morbidity; symptoms such as mucositis, impaired 
swallowing function, declined eating ability, xerostomia, dysgeusia, nausea, and vomiting may 
limit oral intake, and inevitably result in unintended weight loss during radiotherapy and for a 
prolonged period after the treatment.2,6-9 
Nutritional depletion in these patients reduces their tolerance to treatment. Malnutrition in 
head and neck cancer patients was significantly correlated with an increased risk of infections 
in patients undergoing surgery and the occurrence of major postoperative complications.3,10 
In addition, higher mortality and morbidity rates, shorter failure-free survival.11-14 and poorer 
quality of life in all therapies including radiotherapy have been reported.15-17 More specifically, 
unintended weight loss was found to be associated with a higher rate of recurrence and 
second primary tumours of the oral cavity and oropharynx after radiotherapy.13 Weight loss 
was found to be associated with reduced kidney function during cisplatin-containing chemo-
radiotherapy.14 Even though no cause effect relationships was established in this study of 
Lin et al., the findings emphasize the importance of intensive supportive measures beyond 
standard nutrition and hydration intervention. 
It is therefore important to maintain an optimal nutritional status for patients through nutritional 
intervention during oncological treatment. 
Several studies suggested that early and intensive nutritional intervention during radiotherapy 
may be beneficial in terms of decreasing the impact of side effects, decreasing unintended 
weight loss, and improving dietary intake, quality of life and treatment tolerance.6,18-21 According 
to published nutritional management guidelines for head and neck cancer patients, nutritional 
interventions must be initiated before and continued during and after cancer treatment and the 
implementation may be more successful if a dietician is involved.22-24
Although many studies demonstrate the benefits of full nutritional intervention program, 
including dietary counseling, there is little evidence for the potential added value of a 
professional dietician’s support. In the current health care system there is a need to justify 
resources and to demonstrate the effects of individual dietary counseling.
The present study was designed to evaluate the effect of individual dietary counseling (IDC) by 
a dietician for patients with oral cavity, oropharyngeal or hypopharyngeal cancer, undergoing 
radiotherapy before, during and after treatment. The objective was to investigate whether 
individualised dietary counseling by a dietician would better maintain a patient’s body weight, 
and thus prevent malnutrition compared to standard nutritional care (SC).
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Experimental methods
Study design 
A prospective clinical study on the impact of dietary counseling on unintended weight loss, BMI 
(kg/m2) and malnutrition in patients with head and neck carcinomas was carried out between 
January 2005 and February 2007 at the Radboud University Nijmegen Medical Centre. 
Patients with primary squamous cell carcinoma in the oral cavity, oropharynx or hypopharynx, 
age ≥18 years, stage II–IV (International Union Against Cancer TNM classification of 
malignant tumours) were included.25 Patients were treated depending on stage, location of the 
tumour and general health conditions by radiotherapy, combined surgery, and radiotherapy or 
concomitant radio-chemotherapy in accordance with the guidelines of the Dutch Cooperative 
Head and Neck Oncology Group.4,5 
From 2005 till 2007, dietary counseling was given to all patients by a dietician before the start 
of radiotherapy.
Next, patients were assigned to one of the intervention groups based on their postal code. 
One group continued to receive individual dietary counseling by a dietician throughout the 
entire treatment and rehabilitation period (IDC). The other group was passed on to trained 
nurses for standard nutritional care during radiotherapy and thereafter (SC). 
At baseline (the first visit to the outpatient clinic at the departments of Otorhinolaryngology 
or Oral and Maxillofacial Surgery) patients´ characteristics including age, sex, actual body 
weight (kg) and height (m) were registered. Parameters studied from baseline through to 
rehabilitation included body weight (kg), BMI (kg/m2; <18.5 = underweight; 18.5-25 = normal 
range; ≥25 = overweight; ≥30 = obese)26 and malnutrition (unintended weight loss of ≥5% in 1 
month and/or ≥10% in six months).3,27 Body weight was measured on a calibrated one decimal 
Seca scale (delta nr 707; Seca, Hamburg, Germany) wearing lightweight clothing under the 
same conditions. 
Measurements were taken at five pre-determined time points for each treatment modality 
(Fig. 1). 
Nutrition policy
Individual dietary counseling (IDC). 
IDC in the present study is defined as individualised and intensive dietary counseling by 
dieticians focused on maintaining and/or improving a patient’s energy and protein intake. 
Counseling is based on four nutritional guidelines.4,5,28,29 
These guidelines describe treatment-related symptoms that influence dietary intake and offer 
advice on how to deal with these symptoms, including dietary counseling strategies, when 
Figure 1. Data collection: Weight in kg (1-5) measured during diagnosis, treatment, early rehabilitation and 
rehabilitation.
Diagnosis Treatment
Early 
rehabili-
tation
Rehabilitation
1      2                                                   3               4          5
            4 weeks                                6 weeks       2 weeks                               8 weeks
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dietary counseling is necessary and when to start tube feeding (nasogastric/gastrostomy). To 
meet the specific nutritional goals for each patient, individual directions for dietary counseling 
were given. The patient’s energy requirement was estimated at >125 KJ to a maximum of 
167 KJ (>30-≤40 kcal) per kg of actual body weight depending on activities, metabolic stress, 
abnormal losses and treatment. The protein requirement was normally estimated at >1.0 to 
a maximum of 1.5 g of protein per kg ideal body weight depending on bedsores or other 
inflammatory disorders which require extra protein intake. Ideal body weight was estimated 
as follows: (1) if a patient was underweight (BMI<20 kg/m2): ideal weight (kg) = 20 kg/m2 x 
height (m)2; (2) if a patient was overweight (BMI>25 kg/m2): ideal weight (kg) = 25 kg/m2 x 
height (m)2; a patient having a BMI of 20-25 kg/m2 was considered to be of ideal weight. IDC 
involved the prescription of a therapeutic diet with regular food which was adjusted to the 
individual’s usual diet, thereby recognising personal eating patterns, feasible consistency and 
preferences. The dietician would also take other relevant factors into consideration, namely 
the need for alleviation or arrest of local symptoms, as well as psychological factors and 
digestive and absorptive capacity. The prescription included the type, amount and frequency 
of feeding, and specified the energetic/protein level that had to be attained. If a patient’s 
oral intake continued to diminish, energy-and protein-rich oral nutrition supplements were 
supplied separately or together with normal meals. Supplements (high energetic drinks) were 
offered to patients in their preferred flavours, and they were instructed to use them as drinks 
to be consumed between meals or in combination with snacks between meals. When all the 
above mentioned methods were insufficient to maintain the required energy and protein intake 
for patients, nutritional intake was achieved through tube feeding. Gastrostomy tubes were 
used in cases where tube feeding was expected to be necessary for a period longer than 6 
weeks. From the start of radiotherapy until at least 2 months after treatment, patients were 
checked twice before and at least once a week during and after radiotherapy. The dietetic 
consultation consisted of twelve to fifteen visits, but could be arranged more frequently when 
requested. The dietician was available to answer any queries or provide more information. 
When necessary, dietetic domiciliary care was arranged for the subsequent period.
Standard nutritional care by a nurse (SC)
Patients were seen twice by a dietician before radiotherapy (IDC policy) and when radiotherapy 
started they were passed on to SC by a nurse. This is as follows: body weight of each patient 
was measured at least once a week on a calibrated scale wearing lightweight clothing. 
Nutritional advice was based on a guideline specifically focused on treatment symptoms such 
as pain, nausea, xerostomia, mucositis, dysphagia, and how to deal with nutrition. 29
Interventions were mostly focused on evaluating pain due to radiation mucositis and adjusting 
pain medication. When nutritional intake seemed insufficient, advice on high energetic liquid 
nutrition and/or high energetic/protein supplements was given. If the above-mentioned 
methods failed to work, a nasogastric tube was used for patients who had lost more than 10% 
of their body weight. Gastrostomy tubes were used in cases where tube feeding was expected 
to be necessary for a period exceeding 6 weeks. 
The frequency of nutritional advice was at least once a week, but this increased when more 
problems occurred (daily, if necessary, depending on the treatment phase and symptoms). 
Patients were seen at the outpatient clinic or contacted by phone up to a minimum of 3-4 
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four months after the treatment. Trained nurses offered patients support during and after the 
treatment in all areas concerning illness and side effects such as nutritional, psychological and 
skin problems, pain and constipation. This support was supervised by a radiation oncologist.
Statistical analysis
Data processing and statistical analysis were performed using Statistical Package for 
Social Sciences version 16.0 (SPSS, Inc., Chicago, IL, USA). 
The percentage of unintended weight loss was calculated using baseline weight as a reference 
point.
A descriptive statistical analysis was performed for the two groups of patients. Differences 
in the distribution of patients´ characteristics were evaluated by Ҳ2 test. Differences of the 
mean change in outcome between groups and within groups were tested by independent 
and dependent Student´s t test, respectively. Fisher’s exact probability test was performed 
to test the difference in malnutrition between the treatment groups. The level of statistical 
significance was set at p<0.05, two-sided.
The present study was conducted according to the guidelines laid down in the Declaration 
of Helsinki, and all procedures involving human subjects/patients were approved by the 
Committee on Research Involving Human Subjects of the Radboud University Nijmegen 
Medical Centre. Written informed consent was obtained from all subjects/patients. 
Results
A total of thirty-eight patients met the inclusion criteria. The IDC group included twenty patients, 
and the SC group consisted of eighteen patients. Table 1 summarises baseline characteristics 
of the two groups. There were no significant differences between age, height, sex, weight, 
BMI, T stage, N stage, tumour site or treatment. 
Percentage of unintended weight loss
The percentage weight changes for the two groups are shown in Fig. 2. 
The IDC group had a maximum of 3% unintended weight loss 2 weeks after the treatment. 
This was approximately the same for the SC group. Two months after treatment, the IDC 
group started to gain weight (1% weight gain), while the SC group continued to lose 1.5% 
weight. Two months after treatment, weight loss was significantly different between SC and 
IDC (p=0.03). 
BMI
Most of the patients in IDC and SC groups had a normal BMI (18.5 kg/m2≤BMI<25 kg/m2) 
throughout the study (Fig. 3). No patients were underweight (BMI<18.5 kg/m2). BMI for the 
IDC and SC did not differ significantly at any of the time points. 
67
Individual dietary counseling versus standard nutritional care for patients with head and neck cancer
5
Table 1 Baseline characteristics of the patients (Mean values with their standard errors)
IDC (n=20) SC (n=18)
Variable Mean SE Mean SE
Age (years) 63.8 1.9 61.6 2.1
Height (m) 1.70 0.00 1.71 0.02
Gender (male) 14.0 8.0
Weight (kg) 69.3 3.4 71.0 3.8
BMI (kg/m2)* 23.9 1.1 24.0 0.9
<18.5 3.0 1.0 
18.5 – 25.0 10.0 12.0
>25∙0 7.0 5.0
T stage
T2 6.0 11.0
T3 7.0 4.0
T4 7.0 3.0
N stage
N0 9.0 5.0
N≥1 11.0 13.0
Tumor site
Oral Cavity 10.0 3.0
Oropharynx 7.0 12.0
Hypopharynx 3.0 3.0
Treatment
 Radiotherapy 6.0 7.0
Chemo/radiotherapy 6.0 5.0
Surgery/radiotherapy 6.0 6.0
IDC, individual dietary counseling; SC, standard nutritional care. 
*BMI (kg/m2): <18.5, underweight; 18.5–25∙0, healthy weight; >25.0, overweight (WHO).26
Figure 2. Percentage of unintended weight loss as a function of time (mean with their standard errors), with 
baseline as reference. IDC, individual dietary counseling; SC, standard nutritional care. *Mean values were 
significantly different between SC and IDC groups (p=0.03).
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Malnutrition
Table 2 displays the prevalence of malnutrition from diagnosis until 2 months after treatment. 
Before the treatment, four of twenty patients in the IDC group and three of eighteen in the 
SC group were malnourished. During the treatment period, the IDC and SC groups remained 
stable. Two weeks after the treatment, there was a significant difference in malnutrition 
between IDC (0/20) and SC (5/18) groups (p=0.02). 
Two months after the treatment, the highest prevalence of malnutrition was seen for SC group 
(3/18).
The prevalence of malnutrition by T stages is shown in Table 3. No significant differences were 
found between the T stages.
Table 2 Prevalence of malnutrition* in individual dietary counseling (IDC) and standard nutritional care (SC) 
groups from diagnosis until rehabilitation.
Number of patients 
per nutrition intervention
Interval IDC (n=20) SC (n=18) Total (n=38)
Diagnosis 4.0 3.0 7.0
Treatment 3.0 4.0 7.0
Early Rehabilitation   0.0 †   5.0 † 5.0
Rehabilitation 1∙0 3.0 4.0
*Malnutrition was defined as `unintended weight loss ≥5% within one month`.
†Prevalence of malnutrition in IDC and SC groups was significantly different (p<0.05) 
Table 3 Prevalence of malnutrition* per T stage from diagnosis until rehabilitation
Number of patients per T-stage
Interval T2 (n=17) T3 (n=11) T4 (n=10) Total (n=38)
Diagnosis 2.0 3.0 2.0 7.0
Treatment 3.0 3.0 1.0 7.0
Early Rehabilitation 5.0 0.0 0.0 5.0
Rehabilitation 3.0 1.0 0.0 4.0
*Malnutrition was defined as `unintended weight loss ≥5% within 1 month´.
Figure 3. BMI as a function of time (means with their standard errors), with baseline as reference. BMI: <18.5 
= underweight; 18.5–25 = healthy weight; >25 = overweight (WHO).26 IDC, individual dietary counseling; SC: 
standard nutritional care. 
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Discussion
Malnutrition, defined as ≥5% of unintended weight loss/month or ≥10% unintended weight 
loss/6 months, is the most commonly used parameter in clinical practice for head and neck 
cancers.3,27 In the literature, the prevalence of malnutrition is associated with higher mortality 
and morbidity rates, shorter failure-free survival and poorer quality of life among radiotherapy 
patients11-17 It is therefore essential to control unintended weight loss/malnutrition and maintain 
an efficient nutritional status for patients. The present study demonstrates the beneficial effect 
of IDC on weight change, BMI and malnutrition for patients with oral cavity, oropharyngeal and 
hypopharyngeal cancers treated with radiotherapy compared to SC. 
Two different groups (IDC and SC) were compared in the current study. Patients´ characteristics 
were evenly distributed. Treatment-induced side effects of patients receiving radiotherapy to 
the head and neck area peak at the end of the treatment course and continue for 2 or more 
weeks after the treatment.20 This is reflected by a sharp weight reduction during this period, 
which continued until 2 months after the treatment, specifically in SC group, while the IDC 
group started gaining weight 2 weeks after the radiotherapy. There was a significant difference 
in unintended weight loss 2 months after treatment for the SC group compared to the IDC 
group. 
The IDC group started with the same proportion of patients with malnutrition (4/20) v. SC (3/18) 
at diagnosis where malnutrition in the SC group increased over time. A significant difference in 
the prevalence of malnutrition for the early rehabilitation period was seen between the groups 
(p=0.02) which affirms that dietary counseling recovers malnutrition where SC increases 
malnutrition. 
While looking at the overall results of this study, the most striking differences are observed in 
the (early) rehabilitation period. Two months after treatment, weight and BMI in the SC group 
were still declining. In future research, a longer follow-up is therefore required to determine the 
nadir of weight loss and the duration of full recovery. Also, more data about nutritional status 
should be included such as a comprehensive nutritional assessment tool (e.g. subjective 
global assessment or patient-generated subjective global assessment), anthropometric 
measurements (e.g. bio-impedance and/or handgrip) and food intake (e.g. dietary history or 
FFQ). Besides, it should be useful to include other endpoints such as quality of life, mortality, 
response to treatment and length of hospital stay.
These results indicate that IDC significantly contributes to maintaining and improving weight 
loss and malnutrition of head and neck cancer patients undergoing radiotherapy. This is an 
important clinically relevant finding which confirms the research objective of this study. 
A randomised study performed by Ravasco et al.6 produced similar results. The study 
demonstrated that individualised dietary counseling (based on regular foods) for head and 
neck cancer patients´ undergoing radiotherapy is the most effective way of improving a 
patient’s nutritional intake, nutritional status and quality of life by the end of treatment until 3 
months after treatment.
However, Ravasco used the Ottery’s Subjective Global Assessment (unscored patient-
generated subjective global assessment) to determine malnutrition. In this system, 
unintended weight loss is one of the deciding factors besides symptoms, metabolic stress and 
subcutaneous fat. 
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A randomised controlled trial by Isenring et al.20,21 showed that dietary counseling using the 
American Dietetic Association - Medical Nutrition Therapy radiation oncology protocol resulted 
in a significant reduction of unintended weight loss from the start of radiotherapy until 3 months 
after treatment compared with their standard practice (which consisted of general nutritional 
advice by a nurse and a booklet). Furthermore, the present study revealed an improvement in 
nutritional status (patient-generated subjective global assessment), dietary intake and quality 
of life in the dietary counseling group when compared to standard practice. This is the first 
prospective randomised controlled trial. A limitation of the present study is that two different 
tumour locations were involved (gastrointestinal and head and neck cancer).
Dawson et al.30 reported a significant reduction in unintended weight loss in oral cancer patients 
undergoing combined modality treatment (surgery+radiotherapy) with increased dietary 
supervision compared to standard dietary counseling after revising their dietary protocol. 
However, this was not compared to nutritional standard care without dietary counseling. It is 
interesting to note that while there have only been a handful of studies in this area by different 
research teams, they have all demonstrated benefits of dietary counseling like our study.
To summarise, early and intensive IDC produces clinically relevant effects in terms of 
decreasing unintended weight loss and malnutrition compared with SC in patients with head 
and neck cancer undergoing radiotherapy. This is especially the case early after treatment 
and during the rehabilitation period. 
The guidelines used by the Radboud University Nijmegen Medical Centre Department of 
Dietetics for head and neck cancer patients is a useful guide in supplying the level of dietary 
support required.4,5,28,29 In clinical practice, patients should receive regular and individualised 
dietary counseling from diagnosis until at least two months after radiotherapy and probably 
longer. 
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Abstract 
Background
The aim of this study was to evaluate nutritional status, food intake and dysphagia in long term 
head and neck cancer survivors.
Methods 
Thirty-two patients with stage III-IV head and neck cancer patients treated by chemoradiotherapy 
were invited to evaluate nutritional status (malnutrition, relative weight change), food intake 
(food modification; quality), and dysphagia. 
Results 
At a median follow up of 44 months, 6 of 32 patients were at risk for malnutrition. Female 
(p=0.049) and patients with high body mass index before treatment (p=0.024) showed 
more weight loss. None of the 32 patients could eat a “full diet”. Six patients used nutritional 
supplements/tube feeding. Low dysphagia-related quality of life scores were significantly 
correlated to increased food modification (r=0.405; p=0.024).
Conclusions
Nutritional advice in patients with head and neck cancer is still necessary years after 
chemoradiation and should focus on nutritional status, food modification, and quality, accord 
with recommended food groups. 
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Introduction
Side effects of (chemo)radiotherapy in patients with head and neck cancer patients are 
common during and immediately after completion of treatment. Acute symptoms such as 
mucositis, xerostomia, and distortion of taste and smell are frequently reported and may 
limit oral intake and lead to weight loss and dehydration during and directly after (chemo)
radiotherapy.1,2
Although chemoradiotherapy in locally advanced disease of the head and neck results in 
better locoregional control and survival than radiotherapy as single treatment modality, it is 
accompanied by increased toxicity.3,4 
Only reporting the acute side effects of a (chemo)radiation program will clearly be insufficient 
to understand the long term consequences.5 Most late side effects (>90 days after treatment) 
develop within the first 3 years after treatment and few appear or progress even after 3 years. 
Therefore to fully recognize long-term impact on treatment, patients with head and neck 
cancer must be followed for several years.6,7
Dysphagia, xerostomia, osteoradionecrosis, trismus and oesophageal strictures are known 
late side effects in patients with head and neck cancer treated with (chemo)radiation.7,8 
Swallowing dysfunction and aspiration are seen in a high proportion in these patients after 
combined chemoradiotherapy with prevalence estimates ranging from 30 to 100%.8-10 
Dysphagia as a late side effect is stated to be a major concern in stage II-IV patients with head 
and neck cancer treated with chemoradiotherapy and was described as the most important 
adverse factor on quality of life (QOL).11-13 Likewise, food intake seems to be highly affected by 
deterioration of swallowing function until 6 months after chemoradiotherapy.14 The impact on 
malnutrition risk and food intake in the long term (>90 days after treatment) has been reported 
only briefly by a few investigators.5 The purpose of this study was to comprehensively evaluate 
nutritional status, food intake and dysphagia in long-term head and neck cancer survivors 
treated by chemoradiation as we presume that these patients are at risk for malnutrition and 
decreased and/or altered food intake due to dysphagia. Within this framework we conducted 
a cross-sectional study. 
Patients and methods
Study design:
Between May 2003 and December 2007, 77 patients with III–IV TNM stage head and 
neck cancer were treated with curative intent by means of accelerated chemoradiotherapy, 
comprising 68 Gy over 5.5 weeks with weekly cisplatin 40 mg/m2, at the Department of 
Radiation Oncology of the Radboud University Nijmegen Medical Centre (RUNMC). 
Between January and April 2009 a cross-sectional study was carried out. Forty of the 77 patients 
were alive without recurrences or second primary tumor. These 40 patients were invited to a 
multidisciplinary late morbidity clinic to evaluate nutritional status, food intake and dysphagia. 
This study was approved by the research ethics committee of the RUNMC and was therefore 
performed in accord with the ethical standards laid down in the 1975 Declaration of Helsinki, 
as revised in 1983. All patients gave their informed consent prior to study (CMO: 2011/412).
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Nutritional status: Malnutrition risk and “relative weight change”:
Malnutrition risk was assessed with the Malnutrition Universal Screening Tool (MUST), the 
first nutritional screening tool specifically designed to use in all healthcare settings for the 
entire range of adult patients.15 
At the late morbidity clinic each patient’s body weight was measured at 1 decimal with 
lightweight clothing on a calibrated scale (SECA-scale; model 770, Hamburg, Germany). 
Height was self-reported by the patient (cm). Data on body weight prior to chemoradiation was 
collected from each patient’s medical or dietetic record (measured on the same scale under 
same conditions). Body Mass Index (BMI: kg/m2) was calculated.16 Subsequently, “relative 
weight change” was calculated as body weight at the late morbidity clinic minus body weight 
before chemoradiation divided by weight before treatment. 
Food intake: food modification and food quality.
Food modification was measured in accord with “normalcy of diet” from the performance status 
scale for patients with head and neck cancer (PSS-HN). A rating scale in which the subscales 
“normalcy of diet”, ”eating in public” and “understandability of speech” are rated from 0 to 
100, with higher scores indicating a better performance. The PSS-HN has been shown to 
discriminate levels of functioning across a broad spectrum of head and neck cancer and has 
demonstrated good interrater reliability as well as sensitivity to differences in performance and 
change over time.17 
Food intake over the previous month was evaluated by means of a dietary history by the
dietician. This is a distinguished method to measure food intake18 Food consumption data
were collected by a well-trained dietician, skilled in the identification of available foods,
meals and food preparation techniques. During a face-to-face interview by means of a 24-
hours record, previously written down by the patient, food intake and food pattern were 
checked. In-depth questionnaires about the quantity and quality of mean food intake over 
the last month were used. 
The contents of household utensils were conversed to “standard household portions sizes” 
to register the quantity of food intake.19 Food items were coded in accord with the Dutch 
food composition database, NeVo 2011, The Netherlands and calculated with “Vodisys” 
(medical software 1.3; Vodisys, Groningen, The Netherlands).20 Subsequently, food intake 
was categorized following the labeling of the “recommended food groups” by the “Dutch food 
based dietary guideline” for qualitative food evaluation.21 
The classification of “recommended food groups” categorized for sex and age was followed, 
which covers vitamins and mineral requirements. Intake of ≥75% of the recommended food 
group was determined to be in accord with requirements. 
Dysphagia:
Swallowing assessment was carried out by a speech-language pathologist with additional 
video fluoroscopy at the Department of Radiology to assess the swallowing act. Also the 
MD Anderson Dysphagia Inventory (MDADI) questionnaire was filled in by patients. This is a 
validated and reliable self-administered questionnaire, designed specifically for evaluating the 
impact of dysphagia on the QoL (global; emotional, functional and physical) of patients with 
head and neck cancer rated from 0 to 100, with higher scores indicating a better performance.22 
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Statistical analysis: 
Normally distributed continuous variables were expressed as means and SD. Differences of 
the mean change in outcomes between 2 groups were tested with the independent Student’s 
t test. Pearson chi-square and Fisher’s exact test were used for ordinal data. The Pearson 
correlation coefficient and the Spearman correlation coefficient were used for correlation.
Data processing and statistical analysis were performed using the statistical software 
Statistical Package for the Social Sciences (SPSS 17.0; SPSS Inc., Chicago, IL, USA).
Results
Thirty-two of the 40 invited patients with head and neck cancer visited the late outpatient 
morbidity clinic at the Department of Radiation Oncology, RUNMC. Median follow-up after 
chemoradiation was 44 months (range 14-68). Table 1 represents patients and treatment 
characteristics of the 77 eligible patients compared to the 32 patients of our study population; 
no significant differences were found. Twenty patients had had dietetic counseling at some 
point in time during or after chemoradiotherapy but, not longer than 3 months after treatment. 
No structural dietetic counseling was given. 
In accord with the MUST, 2 patients were at high risk and 4 patients had a medium risk of 
malnutrition. Five of these evaluations were based on a “BMI<18.5 or 18.5-20.0” and 1 patient 
due to “5 to 10% involuntary weight loss during the last 3-6 months”. 
Mean weight before chemoradiotherapy started was equal to the mean weight at the late 
morbidity clinic: 73 kg (SD 14.6) and 73.4 kg (SD 14.9), respectively. However, 16 patients 
had lost weight and 16 patients had been stable or gained weight since the start of 
chemoradiotherapy until the late morbidity clinic. The mean difference in relative weight loss 
(9%; SD 5%) and relative weight gain (10%; SD 9%) between the 2 groups was statistically 
significant (p<0.001). Patients were dichotomized in these 2 groups (Table 223). Differences 
between patients’ characteristics for those 2 groups were tested and a significant difference 
for sex (p=0.049) and a higher BMI (>26.3) before chemoradiation were found in patients with 
weight loss (p=0.024). 
Data from the late morbidity clinic were collected at different time intervals (14-68 months 
follow-up), but no significant correlation for relative weight change and time interval was found 
(r=0.148; p=0.42). 
PSS-HN measurements are given in Table 3. They revealed that none of the patients could 
eat a “full diet” without restrictions. Six out of 32 patients (19%) could eat only soft foods 
(score 40-50). Twenty-four of the 32 patients (75%) could eat only with mild to moderate 
modifications. Difficulties with “eating in public” were present in 11 of 32 patients (34%) (PSS-
HN ≤50). 
Food quality has previously been categorized in accord with the Dutch food-based dietary 
guidelines for age groups (19-50 years, 51-70 years and ≥71 years) and sex.
In general greens, bread, potatoes/rice/pasta/legumes, milk products, cheese and low fat/diet 
margarine were far beneath recommended food intake (Table 4).
In 10 of 32 male patients a mean alcohol intake of 390 mL (SD 168; 1-4 alcohol units/day) was 
found. All of the consumers drank beer. 
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Table 1 Patient and treatment characteristics of all 77 patients and 32 patients at the late morbidity clinic.8
Characteristic All 77 patients (%) 32 participants at the late morbidity clinic 
(%)
Sex
Male 58 (75) 23 (72)
Female 19 (25) 9 (28)
Mean age, y (range) 55 (32-72) 55 (32-69)
Primary tumor site 
Oral cavity 12 (16) 2 (6)
Oropharynx 12 (53) 21 (66)
Hypopharynx 41 (30) 9 (28)
Larynx 23 (1) 0 (0)
T classification
  T1 2 (3) 0 (0)
  T2 10 (13) 7 (22)
  T3 33 (43) 14 (44)
  T4 32 (42) 11 (34)
N classification
N0 7 (9) 3 (9)
N1 10 (13) 3 (9)
N2a 3 (4) 1 (3)
N2b 20 (26) 9 (28)
N2c 30 (39) 14 (44)
N3 7 (9) 2 (6)
TNM Stage
III 9 (12) 3 (9)
IV 68 (88) 29 (91)
Irradiation dose 
54 Gy 1 (1) -
68 Gy 76 (99) 32 (100)
Irradiation technique
IMRT 13 (17) 9 (28)
3D-conformal 54 (83) 23 (72)
Courses cisplatin
<3 0 (0) 0 (0)
3-4 10 (13) 3 (9)
>4 67 (87) 29 (91)
Tube feeding*
Before treatment 27 (35) 9 (28)
During treatment 37 (35) 16 (50)
Median duration in weeks 
(range)
 10 (1-76) 10 (3-76)
Abbreviation: IMRT, intensity-modulated radiotherapy. *Indication tube feeding: more than 10% weight loss or 
patients who could only swallow liquids before the start of therapy. 
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Table 2 Patient characteristics for patient with and without relative weight loss
Characteristic Total no. 
of patients 
(n=32)
No. of 
patients with 
weight loss 
(n=16)
No. of patients 
with stable 
weight/gained 
weight (n=16)
p value
Sex (n[%]) 0.049*
Male 23 (72) 9 (39) 14 (61)
Female 9 (28) 7 (77) 2 (23)
Age (mean y, SD) 58 (9.1) 58 (10.7) 58 (7.4) 0.955
TNM stage (n[%]) 23 1.000
II 7 (22) 4 (25) 3 (19)
III 14 (44) 7 (44) 7 (44)
IV 11 (34) 5 (31) 6 (37)
Tumor location (n[%]) 0.170
Oral cavity 2 (6) 0 (0) 2 (13)
Oropharynx 21 (66) 13 (81) 8 (50)
Hypopharynx 9 (28) 3 (19) 6 (37)
BMI before chemo radiation  
(mean [SD])
 24.3 (5.2)  26.3 (5.1) 22.2 (4.6) 0.024*
Mean relative weight change 
(percentage [ SD])
1 (12) -9 (5) 10 (9) <0.001*
Score MUST (n[%]) 0.461
(mean [SD])Low risk (0) 26 (81) 12 (75) 14 (88)
(mean [SD])Medium(1) 4 (13) 3 (19) 1 (6)
(mean [SD])High risk (≥2) 2 (6) 1 (6) 1 (6)
PSS-HN Normalcy of food intake ≤50 
(n[%]) 
8 (25) 5 (31) 3 (19) 0.480
Tube feeding in history (n[%]) 25 (78) 11 (69) 14 (88) 0.549
Dysphagia (n[%])† 24 (75) 13 (81) 11 (69) 0.683
Impaired video fluoroscopy (n[%]) ‡ 17 (57) 9 (60) 8 (53) 0.808
MDADI (global) ≤50 (n[%]) 9 (28) 6 (37) 3 (19) 0.317
Abbreviations: BMI, body mass index; MUST, malnutrition universal screening tool; PSS-HN, performance 
status scale for head and neck cancer patients; MDADI, MD Anderson Dysphagia Inventory.
* Significant (p<0.05).
† Based on clinical research by a speech-language pathologist.
‡ Based on video fluoroscopy (n=30).
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Tube feeding from start of chemo radiotherapy until late morbidity clinic was used in 25 patients 
(78%), at some point with a median period of 10 weeks (mean 21, SD 23). At the late morbidity 
clinic, 6 out of 32 patients (19%) used nutritional supplements of which 2 used complete tube 
feeding, without any oral intake. One patient used tube feeding by a jejunum tube and 1 patient 
by a percutanous radiologic gastrostomy. Four patients used 1 to 4 packages energy drinks a day. 
In 24 patients (75%), dysphagia was found based on clinical assessment by a speech-
language pathologist. Videofluoroscopy, performed in 30 patients who were able to swallow, 
showed that 17 patients (57%) had impaired swallowing (Table 2). Mean MDADI global 
functioning was 73 (SD 29). No correlation was found for impaired swallowing malnutrition 
risk (MUST), “relative weight change” or food modification (PSS-HN). However, lower MDADI 
scores, global, showed a significant correlation with lower food modification scores (PSS-HN) 
(r=0.405; p=0.024 ). 
Table 3 Performance Status Scale for all head and neck cancer survivors at the late morbidity clinic (n=32). 
Characteristic No. of 
patients 
(%)
Normalcy of diet
100 full diet (no restrictions)  0 (0)
90 peanuts  7 (22)
80 all Meat 10 (31)
70 carrots, celery  3 (9)
60 dry bread and crackers  4 (13)
50 soft, chewable foods (eg, macroni, canned soft fruits, cooked vegetables, 
fish, hamburger, small pieces of meat)
 5 (16)
40 soft foods requiring no chewing (eg, mashed potatoes, apple sauce, pudding)  1 (3)
30 pureed foods (in blender)  0 (0)
20 warm liquids  0 (0)
10 cold liquids  0 (0)
0 non oral feeding (tube fed)  2 (6)
Understandability of speech
100 understandable 18 (56)
75 understandable most of the time; occasional repetition necessary  9 (28)
50 usually understandable; face-to-face contact necessary  4 (13)
25 difficult to understand  1 (3)
0 never understandable; may use written communication  0 (0)
Eating in public
100 no restriction of place, food, or companion (eats out opportunity)  21 (66) 
75 no restriction of place, but restricts diet when in public (eats anywhere, but 
may limit intake to less “messy” foods (such as liquids)
 1 (3)
50 eats only in the presence of selected persons in selected places 6 (19)
25 eats only at home in the presence of selected persons  2 (6)
0 always eats alone  2 (6)
Note: The score a patient receives is the highest possible score for this patient.
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Discussion
The purpose of this study was to comprehensively evaluate nutritional status, food intake and 
dysphagia in long-term head and neck cancer survivors treated by chemoradiation, given that 
we presume that these patients are at risk for malnutrition and decreased and/or altered food 
intake due to dysphagia. 
The outcome of this study showed that 6 out of 32 (19%) patients were at risk for malnutrition 
(MUST); of these, 2 patients were at high risk. Five of these patients were at risk in accord 
with their low BMI; this probably occurred as a result of weight loss during and shortly after 
treatment, and for some reason they could not gain weight thereafter. 
The patient group was dichotomized between those who had weight loss (n=16) and those 
with stable weight or weight gain (n=16) (Table 2). However, it is unknown whether weight 
loss was intentional/desirable for these patients. Patients with higher BMI before the start of 
chemoradiation 26.3 (SD 5) (p=0.024) and more females (p=0.049) were found in the group 
with weight loss. Weight loss in overweight/obese patients may not necessarily be desirable, 
particularly in older patients who may experience a disproportionate loss of lean muscle mass, 
leading to sarcopenic obesity and concomitant frailty.24 In patients with head and neck cancer 
Table 4 Qualitative food evaluation, mean values of food intake in food groups (n=32) and total patients with 
food intake in accord with ≥75% of the recommended food groups.
Food groups Mean 
values of 
food intake 
(mean [sd])
 (n=32)
No. of patients with 
food intake (≥75%) 
in accord with 
recommendation 
(n [%])*
Greens (g) 126 (72) 4 (13)
Fruit (g) 108 (269) 18 (56)
Bread (g) 116 (70) 12 (38)
Potatoes, rice, pasta,  legumes (g) 123 (71) 14 (44)
Milk products (mL) 379 (276) 14 (44)
Cheese (g) 22 (24) 10 (31)
Meat/cold cuts, fish, chicken, eggs, meat, substitutes (g) 136 (84) 27 (84)
Low fat/diet margarine (g) 12 (11) 7 (22)
Fats and oils for baking/frying (g) 21 (20) 19 (59)
Liquids (mL) 1894 (745) 24 (75)
 “Miscellaneous” (g)† 34 (33) n.r.
Alcohol (mL)‡ 122 (204) n.r.
Nutritional supplements (mL)‡ 144 (383) n.r.
Abbreviation: n.r., no requirements.
* Based on individual patients in accord with `Dutch food-based dietary guidelines- recommended food groups` 
for age groups and sex.
†All food items not belonging to 1 of these groups (eg, snacks, sugar, jams, chocolate sandwich spreads) were 
put under “miscellaneous”. For these groups there are no requirements (n.r.).
‡ Alcohol and nutritional supplements (tube feeding, diet formula and energy drinks) were added as separate 
groups. For these groups there are no requirements (n.r).
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treated with radiotherapy, either alone or combined with chemotherapy or surgery, Jager-
Wittenaar et al25 found that a higher fat mass at baseline is significantly related to loss of 
lean mass during treatment (r=0.51, p=0.005). This can indicate that extra support is needed 
for patients, especially woman, with a high BMI at the start of treatment. Due to the cross-
sectional study design median follow-up after chemoradiation was 44 months with a range of 
14 to 68 months. It should be mentioned that this was a highly heterogeneous time interval 
after the treatment period. However, there seemed no significant correlation with time interval 
and relative weight loss. 
Food modification varying from mild to serious was necessary for all 32 patients. Six patients 
still used nutritional supplements or tube feeding (19%), 2 of them had no oral intake at all. 
This is in line with a study of Beeken en Calman,26 who reported that 72% of patients required 
modifications of dietary consistency in oropharyngeal cancer treated with curative intent at 
a mean follow up of 3.5 years. Rademaker et al27described that 89% of the patients were 
able to eat orally and only 48% of patients (44/90) of patients could eat all foods (without 
modifications) until 12 months after (chemo)radiation (based on patients’ reports). In contrast, 
a retrospective study carried out by Akst et al28 found that, 24 months after chemoradiotherapy 
treatment, 7 of the 116 patients (6%) used tube feeding and 91% of patients (106/116) could 
eat a “normal diet”. However, “normal diet” was not clarified. 
In general, greens, bread, potatoes/rice/pasta/legumes, milk products, cheese, and low fat/diet 
margarine are far below the recommended food intake (Table 4). This is partially in line with 
the general Dutch population, in accord with the Dutch National Food Consumption Survey 
(2007-2010), where an insufficient intake of fruit, greens, fish and fiber is found.29 So far no 
other literature has been found on the intake of food groups in patients with head and neck 
cancer after (chemo)radiotherapy. Accord to the report of the World Cancer Research Fund, 
nonstarchy vegetables and fruit in general protect against cancers of the mouth, pharynx, 
and larynx (R²=0.72, confidence interval [CI]=0.63-0.82 per 50 g/day). In addition, there is 
consistent evidence for a dose-response relationship, whereby alcoholic drinks are a cause of 
mouth, pharynx, and larynx cancers (R²=1.24, CI=1.18-1.30); this applies to beer in particular 
(R²=1.06, CI=1.03-1.08).30 Advice on the recommended vegetable and fruit intake also after 
treatment should therefore be emphasized. This applies also to the explicit benefit of alcohol 
limitation to decrease the risk of a secondary tumor. All this should be taken into account in 
nutritional advice in the long term. 
In our study, dysphagia was present in 75% of the patients of whom 57% had impaired 
swallowing based on videofluoroscopy. Impaired swallowing was not correlated with 
malnutrition risk, “relative weight loss” or food modification. However lower global MDADI 
scores (higher impact of dysphagia on QoL) were significantly correlated with lower food 
modification scores (PSS-HN) (r=0.405; p=0.024 ). Langendijk et al13 found that QOL (EORTC) 
was significantly affected by late radiation-induced adverse effects (RTOG swallowing), grade 3 
and 4 (fluids only and tube feeding, respectively). In spite of different questionnaires used, this 
almost shows the same results.
The current study indicates that malnutrition risk and weight loss still exist, especially in females 
and patients with high BMI before chemoradiation. A high degree of food modifications, use of 
nutritional supplements/tube feeding is still present in head and neck cancer survivors treated 
with chemoradiotherapy. Qualitative food intake based on food groups is far beneath the food 
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recommendations. A higher impact of dysphagia on QOL was correlated with lower normalcy 
of food intake. 
Despite the small study population, this study gives unique information on nutritional status, 
food intake and dysphagia in head and neck cancer survivors in the long term, which is 
educational for dieticians/nutritionists and the awareness of the total multidisciplinairy head 
and neck oncology team. We conclude that nutritional advice for the patients with head 
and neck cancer is still necessary for a long time after chemoradiation and should focus on 
malnutrition risk and weight loss, food intake with normal food consistency without nutritional 
supplements/tube feeding, and recommended food groups. 
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Abstract
 
Purpose
Dysphagia resulting in diminished or altered oral food intake requiring tube feeding is common 
among head and neck cancer patients. This randomized clinical trial investigated the effect 
of combined individual dietary counseling with individual swallowing therapy (intervention) 
compared to individual dietary counseling alone (control) on normalcy of food intake (NFI).
Patients and methods
Patients with stage II-IV head and neck cancer treated with primary or postoperative (chemo)
radiation were randomly assigned to the intervention or control group. NFI was defined as food 
intake without tube feeding, dietary energy drinks/supplements or modified foods. Dysphagia 
severity, social eating, and nutritional status were also measured at the start of treatment and 
in weeks 6, 10, 18 and 30.
Results
Patients were recruited from March 2010 through April 2012. NFI was achieved at week 30 in 
63% and 51% of patients in the intervention and control groups, respectively; the difference 
in NFI was 5.3 (95% CI: -4.2 to 14.9) in favor of the intervention group. The percentage of 
patients requiring tube feeding was low in the total study period in both the intervention (24%) 
and control (19%) group. No overall estimated difference was detected for dysphagia severity, 
social eating, or nutritional status. At week 10, the intervention group had improved recovery 
of dysphagia compared to the control group 0.6 (95% CI: 0.1 to 1.1), although this difference 
diminished by week 30. 
Conclusion
This study demonstrates that adding individual swallowing therapy to individual dietary 
counseling does not improve normalcy of food intake but accelerated swallowing recovery. 
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Introduction
Patients with head and neck squamous cell carcinomas (HNSCC) often suffer from impaired 
oral food intake due to tumor symptoms and side effects of the treatment.1-3 Dysphagia is 
one of the most prevalent and serious complications that can arise during and following 
radiation therapy and can severely restrict food intake.4-7 Temporary tube feeding, the use of 
oral nutritional supplements, and/or food modifications can be necessary to ensure adequate 
nutrient intake.8 However, resuming normal oral feeding after tube feeding can be difficult as 
a result of chronic dysphagia.4,9
Any deviation from normal food intake can decrease quality of life. For example, increased 
eating time, considerable messiness with food, and reluctance to eat in public can have a 
negative impact on the patient’s quality of life.4,10-12 Achieving normal food intake, which is 
defined as regular full oral intake without the need for tube feeding, energy drinks/supplements 
or modified foods, is therefore an important goal for patients with HNSCC.
Some prospective studies have suggested that preventive swallowing therapy can have a 
beneficial effect on swallowing function in patients with HNSCC who are treated with (chemo)
radiation.13,14 Swallowing therapy can be effective at decreasing dysphagia severity, thereby 
reducing the need for tube feeding and improving oral food intake.15,16 We hypothesized that 
combining individual dietary counseling with individual swallowing therapy during and after 
(chemo)radiation can improve the patients’ normalcy of food intake (NFI). 
This randomized clinical trial evaluated whether concerted multidisciplinary treatment with 
individual dietary counseling and swallowing therapy improves NFI in patients with HNSCC 
treated with primary or postoperative (chemo)radiation compared to individual dietary 
counseling alone. 
Patients and methods
Eligibility and Assignment
This study was performed at the Radboud University Nijmegen Medical Center and was 
approved by the university’s research ethics committee (ABR: 28638.091.09). This study was 
registered at ClinicalTrials.gov (FOCISD: NCT01110980). Patient eligibility was assessed by 
the multidisciplinary head and neck oncology team.
Eligibility criteria: Patients ≥18 years of age with stage II-IV (UICC TNM-tumor classification) 
squamous cell carcinoma of the oral cavity, nasopharynx, oropharynx, hypopharynx or larynx 
and who received curative treatment with primary or postoperative (chemo)radiation were 
eligible.
Exclusion criteria: Patients with previous head and neck carcinoma treated by primary or 
postoperative (chemo)radiation or surgery, neurological or other non-tumor-related swallowing 
problems, an inability to comprehend and/or perform swallowing therapy and instructions and/
or an inability to answer the study questionnaires. 
Each patient provided written informed consent prior to randomization. Eligible patients were 
randomly assigned to either the intervention group or the control group at a 1:1 ratio using a 
computer-controlled randomization process with minimization of the following three potential 
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confounding variables: tumor location, tumor stage, and tumor treatment. 
The patients, dieticians, and speech-language pathologists were aware of the treatment 
allocation. The patients were treated in accordance with the guidelines of the Dutch Head and 
Neck Society. 
Control group: Individual dietary counseling (standard care)
The patients in the control group received standard care, defined as individualized intensive 
dietary counseling by a dietitian who focused on maintaining and/or improving the patient’s 
energy and protein intake according to the patient’s requirements.17 The patient’s energy 
requirement was estimated as described by Harris and Benedict (1984) with an additional 
30-50%.18 During treatment, each patient received dietary counseling each week and during 
the rehabilitation period at least every two months (or more frequently as needed) following 
protocol.17
Intervention group: Combined individual dietary counseling with individual 
swallowing therapy
Patients in the intervention group received the same individualized intensive dietary 
counseling as the patients in the control group. In addition, these patients received individual 
swallowing therapy by a speech-language pathologist to compensate for consequences of 
the tumor or (chemo)radiation on the efficacy and safety of oropharyngeal swallowing. The 
swallowing therapy consisted of the following interventions: (a) stretching exercises designed 
to maximize lip, tongue and jaw mobility; (b) compensations and swallowing maneuvers such 
as adapted head posture and supraglottic swallowing (e.g., to compensate for aspiration if 
needed)19; and (c) adaptations of food consistencies if needed. Patients who were at risk for 
aspiration or had substantial dysphagia and were (completely) dependent on tube feeding or 
modified food intake were supported by the speech-language pathologist to ensure safe oral 
intake with optimum food modification. Simultaneously, the dietician provided advice regarding 
maintaining and/or improving the patient’s energy and protein intake according to the patient’s 
requirements, with tube feeding and energy drinks/supplements reduced as much as possible. 
The intervention sessions occurred from the first week of (chemo) radiation and lasted for 30 
weeks. Patients were seen weekly during (chemo)radiation and were instructed to perform 
their exercises daily; after (chemo)radiation, patients were seen every two months and were 
monitored weekly through telephone sessions. 
Data collection
Data were collected in week 0 (the first week of treatment), week 6 (the last week of treatment), 
week 10 (one month after treatment), week 18 (three months after treatment) and week 30 
(six months after treatment).
Normalcy of food intake (NFI) 
NFI was measured using the PSS-HN-normalcy of diet and NFIS-HN-F (Appendix 1).20-22 
PSS-HN is a validated clinician-rated instrument with the following three subscales: normalcy 
of diet, eating in public, and understandability of speech.20 PSS-HN-normalcy of diet was used 
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to report food modification, with a score of 100 reflecting optimum NFI. The NFIS-HN-F score 
was calculated based on the mean values of a two-day food diary (one weekend day and one 
non-weekend day) that was reported by each patient. The amounts consumed were measured 
in milliliters or grams.23 The food diary was “cross-checked” by the dietician. The food items 
were coded, and energy intake was calculated according to the Dutch Food Composition 
Database.24 The optimum NFI according to the NFIS-HN-F was defined as a score of 6. 
Dysphagia severity
Dysphagia severity was measured using the NFIS-HN-L, a clinician-rated oral intake scale 
specific for HNCP (Appendix 1).21,22 The M.D. Anderson Dysphagia Inventory (MDADI) a 
validated and self-administered questionnaire for patients with HNSCC, was used to assess 
the impact of dysphagia on the patient’s quality of life.25 To measure swallowing capacity, the 
swallowing velocity and swallowing volume tests were performed.26,27 
Social eating 
PSS-HN-eating in public was measured to identify quality of life issues with respect to the 
patient’s ability to share meals with others.20 
Nutritional status
Nutritional status was measured as check for good nutritional care. Each patient’s body 
weight was measured on a calibrated SECA scale (model 770, Hamburg, Germany), while 
wearing lightweight clothing. Height was measured with a SECA ruler (type DBGM, Hamburg, 
Germany). The patient’s body weight six months prior to the start of treatment was retrieved 
from the patient’s medical file, and “relative weight change” was calculated as the percent 
weight change relative to the weight at week 0. Body Mass Index (BMI) was calculated using 
the formula kg/m2.28 Malnutrition was measured at week 0, week 18, and week 30 and was 
defined as the presence of at least one of the following criteria: a) unintentional weight loss of 
≥5% in one month and/or ≥10% in six months; b) BMI≤18.5 in patients under the age of 65; 
and c) BMI≤20 in patients age 65 years or older.29 
Statistical methods
The Mann-Whitney U-test was used to test difference in the patient characteristics between 
the therapy groups for statistical significance in the case of continuous variables and the 
Pearson’s chi–squared test in case of two by two tables. 
Prior to the analyses, the swallowing volume and the swallowing velocity was put to zero for 
those patients who were not able to swallow or did not dare to swallow.
A linear mixed model for repeated measurements was used to study the differences between 
the two treatment groups for each of the variables regarding “Normalcy of food intake”, 
“Dysphagia severity”, “Social eating” and “Weight change”, separately. The dependent 
variable was the specific variable. The independent class variables were the treatment group 
(two levels) and time point of measurement (four levels). The independent continuous variable 
was the baseline value of the specific variable. Also the interaction term between group and 
time point was included in the model. The intercept of each patient was treated as a random 
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variable to allow a different level for each patient. The estimated difference between the two 
groups with the 95% confidence interval is presented at 10 and at 30 weeks. 
All patients with at least one follow-up measurement were included in the analysis (intention 
to treat).
Statistical analyses were performed using SPSS 20.0 for Windows (IBM, SPSS Inc., Chicago, 
IL, USA).
Sample size 
Based on a difference of ten points on the PSS-HN normalcy of diet scale, two groups of 50 
patients were required to achieve a power of 80% for performing an analysis of covariance 
with baseline as covariate (two-sided testing with α=0.05). This result was based on a standard 
deviation of 25 and a test-retest correlation of 0.7.14,30 Thus, with an estimated withdrawal 
rate of 20%, 120 patients (60 patients per group) had to be enrolled in order to achieve this 
required sample size.
Results 
Patients
One hundred and twenty patients were randomly assigned to either the intervention or control 
group from March 2010 through April 2012, with the last patient completing the measurements 
at week 30 in December 2012 (Fig. 1). Six patients (three from each group) withdrew their 
consent before the first measurement, stating that participation in the study during medical 
treatment would be too demanding. Thus, a total of 57 patients in each group were eligible 
for analysis (Fig. 1). One patient in the control group received swallowing therapy according 
standard care. The baseline characteristics by study groups showed no statistical differences 
(Table 1). The majority of the patients had relatively small T2-stage tumors (68%) and received 
primary radiation (63%). 
The percentage of patients who received tube feeding and energy drinks/supplements is 
presented in Table 2. At the start of treatment, two patients in the intervention group and 
one patient in the control group were already using tube feeding. Eleven patients in the 
intervention group were fed through a nasogastric tube, and three patients were fed through 
a percutaneous radiologic gastrostomy; 11 patients in the control group were fed through a 
nasogastric tube. In the first week of treatment, the prevalence of malnutrition was significantly 
higher in the intervention group (p=0.03); in weeks 18 and 30, the prevalence of malnutrition 
was similar between the two groups (Table 2).
Swallowing intervention 
The intervention group received an average of nine (SD=3.6) swallowing therapy sessions, 
with a minimum of 4 and a maximum of 21 sessions; only five of the patients (8%) required 11 
or more sessions. Except for the stretching exercises, the majority of the interventions (96%) 
were changes in head posture and food consistency. Nine of the patients (15%) needed to use 
a swallowing maneuver in order to achieve safe swallowing.
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Figure 1. CONSORT diagram. Intervention: combined individual dietary counseling and individual swallowing 
therapy. Control: individual dietary counseling (standard care).
Normalcy of food intake
The observed mean (SD) values of the PSS-HN-normalcy of diet and NFIS-HN-F by point of 
measurements in each study group and the estimated differences between the study groups 
at week 10 and 30 are presented in Table 3. The estimated mean profiles of the PSS-HN-
normalcy of diet and NFIS-HN-F were similar between the intervention and control groups 
(Fig. 2). Although the estimated mean difference in PSS-HN-normalcy of diet at week 30 
was higher in the intervention group than in the control, a difference of 5.3 (95% CI: -4.2 to 
14.9), this difference did not reach the level of statistical significance (Table 3). In addition, the 
percentages of patients with the optimum NFI score at week 30 were nearly identical to the 
percentages at week 0 (Table 4). The percentage of tube feeding was highest in week 10 for 
both groups (intervention: 17%, control: 12%) and then decreased to baseline values by week 
30 (intervention: 3%, control: 0%).
Assessed for eligibility: n=236
  Not meeting inclusion criteria: n=3
  Refused to participate: n=113
Patients randomly assigned: n=120
  Allocated to intervention: n=60
  Received allocated intervention: n=57
  Did not receive allocated intervention  
  (study too demanding): n=3
  Completed study: n=41
  Discontinued intervention: n=16
  -  Recurrence or second primary tumor:      
     n=12
  -  Study too demanding: n=2
  -  Deceased: n=2
  Allocated to control: n=60
  Received allocated intervention: n=57
  Did not receive allocated intervention  
  (study too demanding): n=3
  Completed study: n=45
  Discontinued intervention: n=12
  - Recurrence or second primary tumor:  
     n=6
  - Study too demanding: n=3
  - Deceased: n=3
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Table 1 Baseline characteristics by study groups
Intervention
n=60
Median (range)/n (%)
32 participants at the 
late morbidity clinic 
(%)
Demographic
Age, years 63 (33-83) 60 (40-86)
Male 46 (77) 43 (72)
Disease
T stagea
T2 39 (65) 43 (72)
T3 8 (13) 7 (12)
T4 13 (22) 10 (16)
N stagea
N0 30 (50) 25 (42)
N1 5 (8) 14 (23)
N2 23 (38) 20 (33)
N3 2 (4) 1 (2)
Stage groupinga
II 22 (37) 20 (33)
III 9 (15) 14 (23)
IV 29 (48) 26 (44)
Tumor site
Nasopharynx 3 (5) 3 (5)
Oral cavity 12 (20) 12 (20)
Oropharynx 20 (33) 16 (27)
Hypopharynx 5 (9) 10 (16)
Larynx 20 (33) 19 (32)
Treatment
Radiotherapy 38 (63) 38 (63)
Postop. radiotherapy 9 (15) 9 (15)
Chemoradiation 9 (15) 10 (17)
Postop. chemoradiation 4 (7) 3 (5)
Treatment technique
IMRT* 56 (93) 54 (90)
3D conformal† 4 (7) 6 (10)
Radiotherapy dosis, Gy 4 (6) 65 (5)
Anthropometric
Weight, kg 70 (47-122) 72 (47-118)
Height, cm 175 (151-192) 175 (154-191)
Weight six months prior, kg 76 (45-131) 77 (47-122)
BMI, kg/m2†† 23 (17-40) 24 (16-44)
aStage according to UICC TNM-tumor classification.
*IMRT: intensity-modulated radiation therapy. †3D conformal: three-dimensional conformal radiotherapy.††  
BMI: Body Mass Index.
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Table 2 Tube feeding, energy drinks/supplements, and malnutrition prevalence by study group
Intervention
n (%)/median 
(range)
Control
n (%)/median  
(range)
p value
Tube feeding (yes) 14 (24%) 11 (19%) 0.39a
Energy drinks/supplements (yes) 57 (100%) 54 (95%) 0.59a
Time to onset tube feeding, days c 30 (0-43) 27 (18-131) 0.64b
Duration of tube feeding, days d 33 (5-200) 28 (3-85) 0.37b
Time to onset Energy drinks/supplements, days c 15 (0-143) 16 (0-115) 0.67b
Duration of Energy drinks/ supplements, days d 64 (2-225) 76 (2-219) 0.59b
Malnutrition (yes)
week  0 15 (26%) 6 (10%) 0.03a
week 18 16 (31%) 16 (33%) 0.83a
week 30 10 (24%) 9 (20%) 0.24a
a Pearson’s chi–squared test. bMann-Whitney U-test. 
c From week 0 until preparation use (tube feeding and energy drinks/supplements). 
d Time between start and end of preparation use (tube feeding and energy drinks/supplements). 
Dysphagia severity, social eating and nutritional status 
The observed mean (SD) concerning dysphagia severity and social eating of the NFIS-HN-L, 
MDADI-E/F/P, swallowing volume (ml), swallowing velocity (ml/s), and PSS-HN-eating in 
public by point of measurements in each study group and the estimated differences between 
the study groups are presented in Table 3. With respect to NFIS-HN-L, the mean estimated 
NFIS-HN-L value at week 10 was statistical significantly higher in the intervention group than 
in the control group by 0.6 (95% CI: 0.1 to 1.1); however, this difference diminished by week 
30 (Table 3 and Fig. 2).
Mean profiles of MDADI-E/F/P, swallowing volume, swallowing velocity, and PSS-HN-eating in 
public did not differ significantly between the intervention group and the control group (Table 3 
and Fig. 2). Regarding swallowing velocity and swallowing volume 14% of the measurements 
was missing in the intervention group and 19% in the control group, because patients were 
not able to swallow or did not dare to swallow.
Additionally, in both groups the percentages of patients with optimum scores for dysphagia 
severity and social eating at week 30 were similar to their respective percentages at week 0 
(Table 4). 
Mean weight change profiles were nearly identical between the intervention group and the 
control group; however, at week 30 the intervention group had more weight gain compared 
to the control group 1.34% (95% CI: -0.45 to 3.14), although this difference did not reach the 
level of statistical significance (Table 3 and Fig. 2). 
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Table 3 The observed mean (SD) of the variables regarding “Normalcy of food intake”, “Dysphagia severity”, “Social eating” 
and “Weight change” by point of measurement in each study group and the estimated difference between the study groups at 
weeks 10 and 30, by using a linear mixed model for repeated measurements with adjustment to the baseline value.
Observed Difference in favor of the intervention
Week 0
Mean (SD)
Week 6
Mean (SD)
Week 10
Mean (SD)
Week 18
Mean (SD)
Week 30
Mean (SD)
Week 10
Mean (95% CI)
Week 30
Mean (95% CI)
Normalcy of food intake
PSS-HN-normalcy of diet* 
Intervention 78 (26) 50 (19) 59 (25) 72 (26) 85 (21) -5.0 (-16.1 to 6.1) 5.3 ( -4.2 to 14.9)
Control 75 (25) 50 (30) 60 (29) 76 (25) 79 (24) 0.0 (reference) 0.0 (reference)
NFIS-HN-F†
Intervention 5.5 (0.9) 4.4 (1.1) 4.6 (1.3) 5.2 (0.9) 5.6 (0.7) 0.0 (-0.4 to 0.3) 0.2 (-0.2 to 0.7)
Control 5.6 (0.6) 4.5 (1.3) 4.6 (1.3) 5.2 (1.1) 5.3 (0.7) 0.0 (reference) 0.0 (reference)
Dysphagia severity
NFIS-HN-L††
Intervention 5.1 (1.2) 4.5 (1.1) 4.8 (1.1) 5.0 (1.0) 5.1 (1.0) 0.6 (0.1 to 1.1) -0.1 (-5.2 to 0.3)
Control 5.0 (1.1) 4.2 (1.3) 4.3 (1.2) 4.8 (1.1) 5.1 (1.0) 0.0 (reference) 0.0 (reference)
MDADI-E‖
Intervention 79 (12) 74 (12) 76 (12) 80 (12) 80 (12) -0.4 (-5.0 to 4.2) 0.0 (-0.2 to 0.2)
Control 81 (10) 76 (11) 78 (11) 81 (11) 81 (11) 0.0 (reference) 0.0 (reference)
MDADI-F¶
Intervention 78 (11) 73 (15) 76 (15) 76 (12) 79 (11) -0.1 (-5.4 to 5.1) 0.1 (-0.1 to 0.3)
Control 80 (9) 75 (11) 77 (12) 78 (10) 79 (10) 0.0 (reference) 0.0 (reference)
MDADI-P♯
Intervention 76 (19) 58 (15) 65 (17) 73 (18) 74 (17) -0.3 (-6.5 to 5.9) 0.0 (-0.3 to 0.3)
Control 78 (18) 60 (15) 68 (18) 72 (16) 77 (17) 0.0 (reference) 0.0 (reference)
Swallowing volume (ml)
Intervention 42 (23) 32 (21) 40 (22) 44 (22) 48 (21) -2.5 (-8.8 to 3.8) 5.9 (-1.1 to 12.9)
Control 48 (22) 35 (19) 40 (20) 42 (24) 46 (23) 0.0 (reference) 0.0 (reference)
Swallowing velocity (ml/s)
Intervention 18 (10) 9 (8) 14 (10) 17 (10) 18 (9) -0.0 (-4.0 to 3.8) -2.0 (-5.3 to 1.3)
Control 17 (10) 11 (10) 15 (11) 18 (12) 19 (10) 0.0 (reference) 0.0 (reference)
Social eating
PSS-HN-eating in public
Intervention 78 (26) 45 (24) 58 (26) 72 (28) 82 (25) -6.0 (-18.5 to 6.4) 2.3 (-8.6 to 13.1)
Control 79 (25) 51 (30) 63 (29) 79 (26) 80 (21) 0.0 (reference) 0.0 (reference)
Weight change
Intervention 0 (0) -2.6 (2.8) -5.9 (5.1) -5.5 (5.6) -4.1 (6.7) -1.54 (-3.41 to 3.14) 1.34 (-0.45 to 3.14)
Control 0 (0) -2.7 (3.3) -5.8 (4.8) -6.0 (5.8) -5.7 (6.0) 0.0 (reference) 0.0 (reference)
CI: Confidence interval.
*PSS-HN -Normalcy of diet: Performance Status Scale-Head and Neck-normalcy of diet. Score 0 to 100; a higher score is 
better; †NFIS-HN-F (Appendix 1): Normalcy of Food Intake Scale-Head and Neck-Dietetic part. Score 1 to 6; a higher score 
is better; ††NFIS-HN-L (Appendix 1): Normalcy of Food Intake Scale-Head and Neck-Logopedic part. Score 1 to 6; a higher 
score is better; MDADI: M.D. Anderson Dysphagia Inventory - E/‖ (emotional)F/¶ (functional)P/♯ (physical). Score 0 to 100; a 
higher score is better. PSS-HN –eating in public: Performance Status Scale-Head and Neck-eating in public. Score 0 to 100; a 
higher score is better
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Figure 2. The estimated mean profiles from baseline up to 30 weeks of PSS-HN-normalcy of diet, NFIS-HN-F, 
NFIS-HN-L, MDADI_E/F/P, swallowing volume (ml), swallowing velocity (ml/s), PSS-HN-eating in public, weight 
change after baseline (%) for the intervention group (solid lines) and control group (dashed lines).
The vertical bars indicate one standard error.
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Figure 2. The estimated mean profiles from baseline up to 30 weeks of PSS-HN-
normalcy of diet, NFIS-HN-F, NFIS-HN-L, MDADI_E/F/P, swallowing volume (ml), 
swallowing velocity (ml/s), PSS-HN-eating in public, weight change after baseline (%)  
for the intervention group (solid lines) and control group (dashed lines). 
The vertical bars indicate one standard error. 
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Discussion 
This randomized controlled trial of patients with a stage II-IV HNSCC treated with primary or 
postoperative (chemo)radiation revealed that the addition of individual swallowing therapy 
to individual dietary counseling did not significantly improve NFI. Moreover, the addition of 
individual swallowing therapy did not reduce the severity of dysphagia, nor did it improve 
social eating or nutritional status. However, the severity of dysphagia was decreased more in 
the intervention group at week 10, although this difference diminished by week 30. 
A recent study compared the effect of prophylactic swallowing exercises during chemoradiation 
with post-treatment swallowing exercises and found that prophylactic swallowing exercises 
led to an improvement in PSS-HN-normalcy of diet and PSS-HN-eating in public that lasted up 
to six months after the end of treatment.31 Another trial compared active swallowing exercises 
from the start of treatment with either usual care or sham swallowing therapy in patients with 
head and neck cancer treated with chemoradiation.32 Swallowing musculature (measured 
using T2-weighted MRI) was preserved better in the active swallowing exercise group than in 
the other treatment groups. However, functional oral intake scores did not differ significantly 
between the groups. These studies used rigid training regimes that included up to two daily 
exercises with a speech-language pathologist, irrespective of dysphagia severity. 
One of the most important differences between studies that report a positive effect of 
prophylactic swallowing therapy and our current study is that we included lower staged HNSCC 
Table 4 The number (%) of the patients with an optimum score (i.e., normal) with respect to “Normalcy of 
food intake”, “Dysphagia severity” and “Social eating” by point of measurement, by study group.
Week 0
n (%)
Week 6
n (%)
Week 10
n (%)
Week 18
n (%)
Week 30
n (%)
Normalcy of food intake
PSS-HN-normalcy of diet 
Intervention 31 (54) 4 (7) 11 (20) 18 (35) 22 (63)
Control 26 (45) 8 (15) 12 (24) 19 (39) 21 (51)
NFIS-HN-F
Intervention 39 (68) 9 (15) 18 (32) 27 (52) 30 (76)
Control 44 (77) 14 (25) 16 (30) 26 (56) 31 (68)
Dysphagia severity
NFIS-HN-L
Intervention 34 (59) 14 (25) 22 (40) 22 (43) 17 (42)
Control 28 (49) 14 (26) 10 (20) 17 (35) 22 (49)
Social eating
PSS-HN-eating in public
Intervention 30 (53) 4 (7) 10 (18) 20 (39) 25 (60)
Control 31 (54) 8 (15) 14 (28) 25 (52) 22 (48)
PSS-HN-normalcy of diet: Performance Status Scale-Head and Neck-Normalcy of diet (i.e. equal to 100); 
NFIS-HN-F (Appendix 1): Normalcy of Food Intake Scale- Head and Neck-Dietetic part (i.e. equal to 6); 
NFIS-HN-L (Appendix 1): Normalcy of Food Intake Scale- Head and Neck-Logopedic part (i.e. equal to 
6); PSS-HN-eating in public: Performance Status Scale-Head and Neck-Eating in public (i.e. equal to 
100).
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patients who received primary or postoperative (chemo) radiation. Another possible reason for 
our lack of intervention effect may be the introduction of intensity-modulated radiation therapy 
(IMRT) in the course of our study. IMRT reduces irradiation of the swallowing musculature 
and salivary glands and has a positive effect on saliva production, including a reduction 
in the prevalence of complications such as xerostomia (dry mouth), less sticky saliva, and 
fewer restrictions in the type and amount of food intake until six months after treatment.33 It is 
therefore possible that a beneficial effect of IMRT led to a bias against differences between 
the intervention group and the control group. 
The patients in the control group may also have benefited from individual dietary counseling. 
This strategy may have prevented the need for changing the consistency of the food and/or the 
use of energy drinks/supplements or tube feeding by providing the most optimum alternative 
food to fulfill the patient’s nutritional requirements. In addition, prophylactic gastrostomy 
placement is not included in our standard care. Reactive tube feeding was re-introduced in 
recent years based on published literature and expert opinion34, and in our study this approach 
led to a transition from tube feeding to energy drinks/supplements in 95-100% of patients.
Another possible reason that we were unable to detect any positive effects of swallowing 
therapy is that the swallowing treatment regime used in other studies was more intense 
than in our study.31,32 However, it is very doubtful and unproven yet whether high-intensity 
treatment can be applied as a routine intervention, as the clinical condition of some of these 
patients during and immediately after radiation treatment precludes the use of such intensive 
treatments. 
Evidence regarding the optimal timing and intensity of swallowing therapy is currently absent. 
It is therefore important to identify patients with severe dysphagia who may benefit from—
and are able to undergo—intensive swallowing therapy during and/or after treatment. Maybe, 
extending swallowing therapy beyond radiation treatment will improve patient outcome, as 
patients will start to recover and will better be able—and more motivated—to perform training 
exercises in order to improve their NFI and decrease their dysphagia severity. 
As with any clinical trial, our study has several inherent limitations. First, it was not possible to 
blind the dietician or speech-language pathologist with respect to the treatment allocation due 
to the combined treatment intervention, and this may have led to observation bias. In addition, 
we did not assess compliance in our study. However, a similar study has reported satisfactory 
compliance of preventive swallowing therapy.35
In conclusion, adding individual swallowing therapy to individual dietary counseling during 
radiation treatment of patients with HNSCC did not significantly improve NFI, although it may 
slightly accelerate the recovery of dysphagia following radiation. Our data suggest that the 
use of IMRT and intensive individual dietary counseling with a reactive approach of tube 
feeding may have a positive effect on achieving NFI.
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Table 4 The number (%) of the patients with an optimum score (i.e., normal) with respect to “Normalcy of food 
intake”, “Dysphagia severity” and “Social eating” by point of measurement, by study group.
Score Definition NFIS- HN score
Dietetic Part (F) Logopedic Part (L)
1 NPO*, withhold all oral food and fluids, except 
water (total tube feeding–parenteral nutrition)
Severe dysphagia, swallowing impossible and/or 
severe aspiration
2 Tube feeding in combination with oral 
intake (thick liquid/possibly incl. oral dietary 
supplements) with ≥50% of nutritional intake1 
provided by tube feeding
Dysphagia, great difficulty with food passage2, 
swallowing impossible and/or severe aspiration
3 Soft and/or liquid oral intake (possibly incl. oral 
dietary supplements) with <50% of nutritional 
intake1 provided by tube feeding
Moderate/severe dysphagia, difficulty with food 
passage, heavily needed compensation3 and/or 
risk of aspiration
4 Soft and/or liquid oral intake with ≥50% of 
nutritional intake1 provided by oral dietary 
supplementation (without tube feeding)
Mild dysphagia, difficulty with some food 
passage, some compensation3 needed, and/or 
incidental aspiration
5 Oral intake of all food consistencies with <50% 
of nutritional intake1 provided by oral dietary 
supplementation (without tube feeding)
Minimal dysphagia, difficulty with dry food only
6 Oral intake of all food consistencies without oral 
dietary supplementation or the need for tube 
feeding
Normal, can eat and drink everything as before
PSS-HN-normalcy of diet: Performance Status Scale-Head and Neck-Normalcy of diet (i.e. equal to 100); 
NFIS-HN-F (Appendix 1): Normalcy of Food Intake Scale- Head and Neck-Dietetic part (i.e. equal to 6); 
NFIS-HN-L (Appendix 1): Normalcy of Food Intake Scale- Head and Neck-Logopedic part (i.e. equal to 6); 
PSS-HN-eating in public: Performance Status Scale-Head and Neck-Eating in public (i.e. equal to 100).
Appendix 1
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Summary and general discussion 
Patients with head and neck carcinoma (HNC) have a particularly high risk for developing 
malnutrition due to the location of the tumor and complications that can arise from the 
treatment. This thesis describes six successive studies that focused on weight loss, quality of 
life (QoL), effect of individual dietary counseling, normal food intake, and dysphagia among 
HNC patients, with the goal of improving nutritional care. 
Weight loss
Chapter 2 describes a prospective observational study regarding the time of onset as well 
as the extent of weight loss and energy intake in squamous cell HNC patients from diagnosis 
until six months after treatment; various treatment modalities were followed over time. 
Weight change was evaluated in 47 patients with squamous cell carcinoma of the oral cavity, 
oropharynx, or hypopharynx. During treatment, patients who received chemoradiation (n=3 
patients; mean weight loss was 10.5 kg) or primary radiation (n=19 patients; mean weight loss 
was 3.3 kg) experienced more weight loss than patients who underwent surgery only (n=15 
patients) or received postoperative radiation (n=10 patients). However, the chemoradiation 
results should be interpreted with caution, given the relatively low number of patients in this 
group. From the end of treatment until two months post-treatment, the patients who were 
treated with (postoperative) radiation had considerably more weight loss than patients 
who received surgery or chemoradiation. The HNC patients who underwent surgery alone 
experienced relatively little weight loss (a mean weight loss of 1.5 kg) between the time of 
diagnosis through the treatment, and they regained the lost weight soon after treatment.
Weight loss itself is a reflection of an energy imbalance that can be due to decreased energy 
intake, increased energy expenditure, and/or energy loss. Energy intake decreased from the 
time of diagnosis through the end of the treatment, particularly among the patients who were 
treated by (chemo)radiation. A similar pattern—in terms of decreased energy (and protein) 
intake during (chemo)radiation until one month following the treatment—was reported in a 
previous study.1 In our study, a correlation was found between weight loss and decreased 
energy intake from baseline through the treatment period. However, mean energy intake 
did not decrease below the minimum energy requirements (30-35 kcal per kg body weight2) 
during the treatment (except for chemoradiation patients). Although this calculated energy 
requirement may not predict one’s absolute energy requirements, similar findings were 
reported in other studies in which energy expenditure/kg free fatty mass (FFM) was measured 
at the start, during, and at the end of radiation therapy and followed a U-shaped (triphasic) 
pattern.3-6 Energy expenditure initially decreased during radiation therapy; at the end of 
treatment, energy expenditure increased, possibly due to hypermetabolism (e.g., mucositis, 
inflammation, and/or cancer cachexia). This might explain the observed drop in weight at the 
end of treatment despite optimal energy intake. 
Overall, the treatment modalities that included radiation conferred the highest risk of weight 
loss from the start of treatment through two months post-treatment, and this is likely due 
to radiation-induced symptoms, which can include pain caused by mucositis, xerostomia, 
dysphagia, dysgeusia, and loss of appetite. HNC patients who receive radiation therapy 
should therefore receive additional attention with respect to nutritional care. These results 
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are consistent with previous reports in which radiation and concomitant chemoradiation were 
found to be independent factors for the development of weight loss, and chemoradiation 
was the primary risk factor for malnutrition.7,8 Other risk factors for severe weight loss during 
treatment that were identified in some studies include the site and stage of the tumor (Chapter 
3), higher pre-treatment body weight, dysphagia, anorexia, and odynophagia.9-11
Partly due to the findings in our study (Chapter 2) more intensely structured and expanded 
dietary counseling has now been implemented for patients with HNC at our hospital from the 
time of diagnosis through the rehabilitation period. 
Quality of life
Chapter 3 describes a prospective observational study regarding the relation between 
malnutrition and quality of life for forty-seven patients with cancer of the oral cavity, oropharynx, 
or hypopharynx from the time of diagnosis, end of treatment and six months post-treatment. 
Malnutrition (defined as weight loss ≥10% within 6 months) in this study was found in 19, 32, 
and 11% of the patients respectively at the time of diagnosis, end of treatment, and six months 
after treatment, respectively. Patients with malnutrition scored significantly worse on functional 
scales, including global QoL, cognitive functioning, and fatigue. Malnourished patients also 
performed worse (clinically relevant) in domains such as role functioning and physical, 
emotional, and social functioning. These findings are supported by previous studies in which 
fatigue, physical functioning, role functioning, and social functioning scores were significantly 
worse in malnourished (5% weight loss in three months) stage III-IV HNC patients at the time 
of diagnosis.12 Similar results were reported in a cross-sectional study of post-treatment oral 
and oropharyngeal cancer patients, in which malnourished patients had significantly lower 
scores with respect to physical functioning and fatigue from one to three years after treatment 
(irrespective of the treatment modality).13 Another study of various HNC patients measured 
both weight loss and QoL at baseline and follow-up and found that 10% weight loss during and 
directly following treatment was associated with a significant negative impact on global QoL, 
social functioning, and social eating.14 These results emphasize the importance of minimizing 
weight loss in order to improve the patient’s functional QoL outcome.15
The relationship between malnutrition and both fatigue and physical functioning is not 
surprising, given that malnutrition in HNC patients is characterized by decreased muscle mass 
and muscle function.5,13 Additional symptoms of depression (e.g., emotional functioning) and 
loneliness (e.g., role and social functioning) have also been correlated with weight loss.16,17 
Impaired emotional, role, and/or social functioning may therefore have contributed to the 
weight loss that we observed in our study. 
On the other hand, QoL is multifactorial and has a wide spectrum of predictive factors.18 
Specifically, age, gender, tumor location, treatment modality, emotional state, smoking, and 
alcohol consumption-related toxicity can negatively affect the patient’s quality of life.19 A similar 
effect was also found in the study presented in Chapter 3 with respect to tumor stage and 
treatment modality. 
In our study, symptom scores were significantly higher (i.e., patients had more symptoms 
and/or more severe symptoms) in the malnutrition group at the end of treatment and six 
months after treatment regarding pain, smell and taste alterations, stickiness of saliva, dry 
mouth, coughing, feeling ill and impaired social eating. These symptoms were the sequelae 
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of primary or postoperative (chemo)radiation that led to malnutrition, whereas impaired social 
eating (i.e., eating in public) was likely a consequence of these symptoms.20 
Chapter 4 describes an exploratory analysis of QoL issues in fifty-two HNC patients one month 
after treatment with three different treatment modalities: radiation, postoperative radiation, or 
chemoradiation. The location of the tumors in these patients ranged from the nasopharynx to 
the larynx, and the tumor stages ranged from stage III -IV. 
Sticky saliva, weight loss, dry mouth, use of pain killers, and use of nutritional supplements 
were reported as the worst symptoms/outcome (score>50) one month after the end of 
treatment. These scores were partially supported by the QoL symptom scores (>50) at the 
end of treatment in Chapter 3. Patients in the radiation and chemoradiation group reported 
more serious impairments than the postoperative radiation group, an observation that has 
been confirmed by other studies.7 
In general, the most striking differences between treatment groups revealed problems 
with nutritional intake (in case of appetite loss, swallowing difficulty, use of tube feeding or 
nutritional supplements, and/or weight loss) and impaired oral function (due to xerostomia, 
trismus, sticky saliva, and/or dental problems) which stresses out the need of further 
supportive care. Although the subpopulations in our study were relatively small, our results 
suggest which impairments can be expected to occur in a given treatment modality. One 
month after treatment was chosen for evaluation of QoL, as this is the period in which patients 
generally develop an interest in rehabilitation following an intensive treatment period and 
are willing to resume daily life with all of its obstacles. In some situations, these symptoms 
(including weight loss, dental problems, trismus, and dysphagia) can be ameliorated by the 
use of proper supportive care. On the other hand, some symptoms (such as sticky saliva, 
appetite loss, and xerostomia) are more difficult to manage. For some of these problems the 
dietician can be extremely beneficial. 
Integrating an individualized prospective evaluation—including digital and/or pre-completed 
home QoL questionnaires—from the time of diagnosis until the start of rehabilitation can 
indicate the need for further dietary intervention based on the individual needs of the patient 
(Chapters 3 and 4).21
Effect of individual dietary counseling
Chapter 5 describes a prospective cohort study of 38 patients with T2-4 tumors located in the 
oral cavity, oropharynx, or hypopharynx to investigate the added value of individual dietary 
counseling in addition to standard nutritional care by a nurse with respect to weight loss, 
BMI, and malnutrition. Individual dietary counseling provided by a specialized dietician was 
designed to achieve the patient’s energy and protein requirements and led to a significant 
decrease in weight loss two months after treatment compared to providing standard nutritional 
care. However, because body composition was not assessed, it is unclear whether the weight 
gain that occurred in the individual dietary counseling group by two months post-treatment 
reflected an increase in fat mass, muscle mass, or both. A previous study conducted in the 
Netherlands reported that patients who received sufficient energy and protein intake as a result 
of individual dietary counseling had an increase in body weight that included a 50% increase 
in lean body mass between one month post-treatment and four months post-treatment.1 
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The number of patients with malnutrition (i.e., weight loss ≥5% within one month) decreased 
significantly from the start of treatment until two months after treatment when individual 
dietary counseling was provided, whereas the malnutrition rate increased in the group that 
received standard nutritional care. This finding is consistent with previous studies that found 
that individualized dietary counseling was also associated with decreased weight loss and 
improved intake of energy and protein.22 Two retrospective and three prospective studies of 
HNC patients who were treated with (chemo)radiation revealed that patients who received 
early dietician-led nutritional intervention had lower weight loss scores, fewer treatment 
interruptions, fewer unplanned hospitalizations, and had significant health-related cost 
savings.23-27 Maintaining body weight/nutritional status through intensive dietary counseling 
also resulted in smaller and fewer perturbations in overall QoL scores from the start of 
radiation treatment through three months following the start of treatment.28 These findings are 
consistent with our finding that weight loss greater than 10% is associated with a significant 
decrease in QoL (Chapter 3). 
Changes in total body weight can include changes in body components, FFM and/or fat mass 
(FM), and water content. Although we did not measure body composition in our study, such 
assessments might have supported our findings of malnutrition, as a drop in lean body mass 
can also indicate malnutrition and is associated with a loss of physical performance. Other 
studies have found that a drop in lean body mass accounts for 62-70% of weight loss in HNC 
patients both during and directly after primary or postoperative (chemo)radiation, possibly 
also in the context an elevated inflammatory state.1,5
Our results suggest that at least some of the weight loss could not be prevented either by 
providing nutritional care or by achieving the required nutritional energy intake (Chapters 2 
and 5), a finding that has been reported previously.23-27 This non-preventable weight loss might 
be the effect of decreased energy and/or protein intake, and/or it might be due to tumor-related 
inflammation. Abnormal metabolism resulting from tumor-related inflammation can prevent 
the patient from responding to conventional dietary counseling that is designed to achieve 
the patient’s energy and protein requirements; this is reflected in the recent international 
definition of cancer cachexia: “Cancer cachexia is a multifactorial syndrome defined by an 
ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully 
reversed by conventional nutritional support and leads to progressive functional impairment. 
Its pathophysiology is characterized by a negative protein and energy balance driven by a 
variable combination of reduced food intake and abnormal metabolism.”29 
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`Normal food intake` and dysphagia
Chapter 6 reports the results of a cross-sectional cohort study to describe how nutritional 
status, food intake, and dysphagia were affected in 32 stage III-IV head and neck cancer 
survivors who were treated with chemoradiation with a median follow up of 44 months. 
According to the `Malnutrition Universal Screening Tool (MUST)`, 19% of these patients were 
at risk for malnutrition; in almost all cases, this risk was due to low BMI. Only one patient 
(3%) was malnourished based on recent weight loss acute malnutrition, similar to a previous 
report.10 These findings suggest that the rate of chronic malnutrition is higher than the rate of 
acute malnutrition. Surprisingly, according to the MUST findings, 50% of patients lost weight 
from the start of chemoradiation through the late morbidity clinic, but not within the last six 
months according the MUST findings; it is possible that these patients were either unable or 
unwilling to gain weight. 
Our findings show that none of the survivors could reach “normalcy of diet”; 94% of these 
patients ate mostly soft foods or at least reported minor adjustments in the consistency of their 
food, as measured using the validated Performance Status Scale for patients with HNC.30 
Nineteen percent (6/32) of patients still used nutritional supplements (energy drinks and/or 
tube feeding). When the same cohort was measured using the Functional Oral Intake Scale 
(FOIS), 15.6% had achieved “normalcy of diet”.31 However, the FOIS questionnaire is limited, 
as its use has only been validated in stroke patients, even though it measures valuable 
items such as tube feeding/oral diet in combination with food consistency. Because food 
consistency, the use of nutritional supplements (tube feeding and energy drinks/supplements), 
and dysphagia can reflect the patient’s limitations with respect to oral intake, we developed 
and validated our own tool to measure “normalcy of food intake” as a specific scale (the NFIS 
scale) for patients with HNC (Chapter 7).32,33
Dysphagia was determined using a clinical assessment and was present in 75% of the 32 
patients. Using videofluoroscopy, dysphagia was identified in 57% of the patients. This is 
consistent with another study of HNC survivors in which aspiration was measured in 44% of 
patients based on videofluoroscopy.34 Furthermore, patients who experienced low dysphagia 
related quality of life (M.D. Anderson Dysphagia Inventory) had significantly less food 
modifications. 
Based on the findings in this thesis and in previously published studies, dysphagia can be 
associated with both short-term and long-term decreased (oral) food intake, increased weight 
loss, and decreased quality of life (Chapter 6). 9-11,34 Dysphagia is commonly reported among 
HNC patients before, during, and after their treatment (Chapter 3 and 4). Dysphagia decreases 
oral nutritional intake and therefore leads to weight loss. Weight loss can then further reduce 
swallowing function by decreasing the volume and strength of the swallowing musculature.35 
There are hints in the literature that treating dysphagia using preventive swallowing therapy is 
a promising strategy for improving oral intake and reducing the need for tube feeding, and this 
led to the randomized clinical trial that is described in Chapter 7. 
Chapter 7 describes a randomized controlled trial with a multidisciplinary intervention of 
individual dietary counseling and individual swallowing therapy compared to individual 
dietary counseling only (`usual care`); 120 patients with stage II-IV squamous cell HNC from 
nasopharynx till larynx, treated by (adjuvant) (chemo)radiation were evaluated for their ability 
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to achieve higher “normalcy of food intake” (NFI). No overall significant difference in NFI 
was found between the group that received both dietary counseling and swallowing therapy 
(hereafter referred to as the intervention group) and the group that received dietary counseling 
only (the control group). Six months after treatment, 63% of patients in the intervention group 
and 51% of patients in the control group achieved normal NFI (defined as regular full oral 
intake without energy drinks/supplements or tube feeding and no restrictions such as modified 
foods). 
Overall, the incidence of tube feeding was low, only one-fifth of the total study population 
required tube feeding, and nearly all tube-fed patients (88%) used a nasogastric tube. The 
use of a nasogastric tube was primarily due to the reactive nature of tube feeding (i.e., a 
prophylactic tube was generally not placed prior to the start of treatment, as the tube feeding 
duration use expected to be shorter than six weeks). The low overall incidence of tube feeding 
could have contributed to the highly similar NFI score between the intervention and control 
group, as the added benefit of including swallowing therapy on NFI was expected to reduce 
the incidence of tube feeding in the intervention group. 
Intensity-modulated radiation therapy (IMRT) is a commonly used advanced mode of delivering 
high-precision radiation. IMRT uses computer-controlled linear accelerators to deliver precise 
radiation doses to a malignant tumor—or specific areas within the tumor—while minimizing 
the radiation dose applied to unaffected, critical surrounding structures such as the salivary 
glands and swallowing musculature. Such high-precision delivery decreases the likelihood 
of developing post-radiation xerostomia or dysphagia, and IMRT reduces the need for tube 
feeding.36 IMRT was used in 91% of our patients, and the aforementioned benefits may have 
contributed to reaching a higher NFI level. In addition, individual dietary counseling may have 
contributed to a lower incidence of tube feeding by encouraging patients to use oral intake as 
long as possible in order to ensure that their energy and protein requirements were met; this 
hypothesis was confirmed by a recent study.27 
Our study population was relatively heterogeneous with respect to treatment modality, which 
may have limited our ability to detect a difference between the intervention and control groups 
in terms of improved NFI and lower severity of dysphagia. As in some other studies that 
included only chemoradiation patients, significant differences in favor of including swallowing 
therapy were found in terms of NFI and dysphagia severity.37,38 A subgroup analysis regarding 
treatment modality was not possible, as the power calculation was not suitable for this purpose. 
Dysphagia severity, quality of life, and nutritional status were not estimated to differ between 
the intervention and control groups (Chapter 7). However, one month after treatment, the 
intervention group had improved recovery of dysphagia compared to the control group, 
although this difference dissapeared by six months after the treatment. Many HNC patients 
experience long-term dysphagia following non-surgical treatment.39,40 Therefore, one goal for 
further improvement in this area is to identify the specific patients who suffer from dysphagia 
following treatment and who might benefit from swallowing therapy; such patients could be 
identified by screening for dysphagia severity. 
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Implications for nutritional care in clinical practice
Figure 1 shows mean percent weight loss over time for the HNC patients with or without 
individual dietary counseling. Among the various studies tumor stage were similar and tumor 
locations and tumor treatment were almost similar. However, some factors must be taken 
into consideration. For example, the results described in Chapter 2 included patients who 
received surgical treatment, and only a few patients received chemoradiation; in contrast, the 
other two studies described in this thesis did not include surgical patients (who generally have 
a lower risk of weight loss). In addition, the studies took place in different years. 
A clear difference in weight change following individual dietary counseling was found between 
the studies presented in Chapters 5 and 7; specifically, in favor of chapter 5 were an earlier 
stabilization/reduction of weight loss was achieved. This finding may have been due to the 
more frequent use of feeding tubes in this study (50% of the patients used a feeding tube, 
55% of which were via a gastrostomy), which was the policy of care in that earlier period. In 
contrast, in our study described in Chapter 7, only 20% of all patients used a tube feeding 
(88% of which were via a nasogastric tube). In general, tube feeding can ameliorate weight 
loss, and prophylactic gastrostomy tube feeding in particular can minimize weight loss more 
than reactive nasogastric tube feeding.41 This (reactive approach of) nasogastric tube feeding 
is associated with a lower incidence of (late) dysphagia due to more continued oral swallowing 
with more oral intake and in particular lower incidences of fibroses and late esophageal 
strictures compared to gastrostomy tubes.42 Moreover, reactive nasogastric tube feeding is 
generally initiated later and has a shorter duration due to the negative aesthetic inconvenience 
associated with a nasogastric tube.36-42 
Aside from the reactive approach of nasogastric tube feeding in Chapter 7, a major issue 
is that out-patient contact in the early rehabilitation period (Fig. 1, beyond week 10) is less 
frequent, whereas post-treatment symptoms likely constitute a major restriction that results 
in a steep decline in body weight. Therefore, additional attention should be given to weight 
change in the initial post-treatment months and whenever tube feeding is deemed necessary 
(chapter 4). By implementing these simple strategies, excessive weight loss—and its 
associated adversities can likely be further prevented in individual patients.
Figure 1. Mean percent weight change over time for HNC patients with or without individual dietary counseling 
with first out patient visit at week 0. IDC: Individual Dietary Counseling. Ch: Chapter. Proph. TF: Prophylactic tube 
feeding. Reac. TF: Reactive tube feeding.
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Based on our findings, individual dietary counseling should be improved 
as follows: 
During treatment, dietary counseling (based on reaching the patient’s energy and protein 
requirements) cannot completely prevent weight loss, but it can minimize critical weight loss 
and should therefore be continued as described in the protocol (Chapters 5 and 7).43 Dietary 
counseling in early rehabilitation period until two months thereafter results in a significant 
amelioration of weight loss and malnutrition, provided that the full intake of energy and 
proteins is ensured. Therefore, to prevent malnutrition, intensified dietary counseling in this 
post-treatment period (where the incidence of malnutrition is still relatively high) should be 
continued at the same level as during the treatment period (i.e., on a weekly basis to bi-
monthly basis) until at least two months after treatment. Tube feeding should not be avoided, 
especially particularly during the post-treatment period. It is therefore important to instruct 
HNC patients at diagnosis regarding the fact that tube feeding is a logical—and occasionally 
necessary—treatment element. For most patients, reactive nasogastric tube feeding is 
preferable to prophylactic gastrostomy placement, as the expected period of tube feeding is 
six weeks or shorter. Moreover, nasogastric tubes are associated with higher oral food intake 
and a lower incidence of dysphagia (due to more swallowing) compared to gastrostomy tubes, 
and this allows patients to resume normal food intake sooner, which in turn improves their 
overall quality of life. To further improve the efficacy of individual dietary counseling, future 
research should attempt to further decrease weight loss in the post-treatment period and 
increase lean body mass. In addition, further improvements should be made to achieve near-
normal food intake in order to improve the social aspects of food intake (particularly among 
chemoradiation patients), resulting in a lifelong focus of individual dietary counseling as well 
as other paramedical care aspects such as dysphagia (Chapters 6 and 7).31
Future perspectives
The results of the studies presented in this thesis answered our research questions, but they 
also raised new questions that must be addressed. In particular, future research should be 
aimed at further improving and customizing individualized dietary counseling for HNC patients. 
Three areas for future improvement can be identified and are described below.
Cancer cachexia
The first question that arose was, the extent to which weight loss in HNC patients is the result 
of decreased food intake due to symptoms such as mucositis, xerostomia, dysphagia, and 
decreased smell and taste based on starvation rather than inflammation/cancer cachexia. 
This question is particularly relevant to the treatment period and the first few weeks thereafter, 
when fulfilling energy requirements did not result in total weight stabilization (Chapters 2, 5, 
and 7).
The actual incidence of cancer cachexia in HNC patients is unknown. Indeed, the incidence 
likely depends on the definition used and on the tumor’s characteristics. In recent years, efforts 
have been made to better categorize cancer cachexia, covering the spectrum from precachexia 
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through (refractory) cachexia; however, no clear consensus definition is currently available.2,29 
After validating such a definition, sufficiently powered trials of HNC patients to investigate the 
actual incidence of cancer cachexia will be needed. In the meantime, interventions for cancer 
cachexia based on nutritional support, pharmacological treatment (for example, (hormonal) 
appetite stimulants such as ghrelin), and nutraceuticals (e.g., eicosapentaenoic acid) show 
some promise.44-48 
Muscle mass
A second goal for further improving dietary counseling is to increase the patient’s functional 
muscle mass. A multimodal treatment that combines physical exercise with adequate dietary 
intervention (e.g., energy and protein supplementation) can be supportive.49 Compelling 
evidence suggests that physical exercise is well-tolerated and can be a safe adjunctive therapy 
to ameliorate cancer-related side effects.49 Physical exercise can improve body composition 
(e.g., increased lean body mass), improve overall quality of life, decrease fatigue, and increase 
physical functioning in malnourished patients (Chapter 3).50 Recently, a relatively small 
randomized study of 30 HNC patients found that progressive resistance training for three 
months following treatment led to an increase in lean body mass.51 Randomized controlled 
trials are needed to study the effect of combining physical exercise with adequate dietary 
intervention (to meet the patient’s energy and protein requirements) in HNC patients; such 
studies can reveal the extent to which such a multimodal treatment will benefit this patient 
population before, during, and after treatment.
Normal food intake
Finally, in addition to maintaining and/or improving the patient’s nutritional status, studies 
should focus on improving “normalcy of food intake” and therefore increase the pleasure 
of eating, social eating, and overall quality of life, particularly from early rehabilitation until 
six months after treatment, when many HNC patients lack normal food intake (Chapter 7), 
and even several years after treatment (Chapter 6). One month after treatment, 50-60% of 
patients still experience mild to severe dysphagia, and this condition can last for years after 
treatment (Chapters 6 and 7). 
Further NFI improvement can be achieved by reducing the need for tube feeding, energy 
drinks/supplements and food modification, both improving quality of life and reducing costs. 
However, there is currently a knowledge gap with respect to effective interventions designed 
to prevent and/or solve problems associated with the social aspect of eating.52,53 We should 
establish whether other post-treatment factors can affect “normalcy of food intake”. In addition 
to a physical approach, interventions that address the psychological and/or social aspects of 
eating should be developed and evaluated holistically in order to help patients cope with any 
lingering eating difficulties. These lifelong aspects merit further attention in future research 
and in programs for educating dieticians and other paramedical health care professionals who 
work with HNC patients.
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Conclusion
Weight loss and malnutrition during and following treatment are highly prevalent among 
stage II-IV HNC patients, and these clinical features can become more severe during the 
end of treatment and the early rehabilitation period, particularly with treatment modalities that 
include (chemo)radiation. Malnutrition is associated with significantly poorer overall quality of 
life, fatigue, and impaired cognitive functioning. Individual dietary counseling is an effective 
approach for curtailing weight loss and malnutrition. Due to intensified treatment strategies, 
many HNC patients suffer from symptoms that can prevent normal oral food intake, which 
can lead to malnutrition and decreased quality of life; with severe dysphagia as one of the 
most prominent symptoms. Despite expectations, combined swallowing therapy to individual 
dietary counseling does not improve the patient’s return to normal food intake. 
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Patiënten met tumoren in het hoofd-halsgebied (HHT) lopen een groot risico op ondervoeding 
vanwege de locatie van de tumor en de bijwerkingen die kunnen ontstaan tijdens of direct na 
de behandeling. Dit proefschrift beschrijft zes opeenvolgende studies naar gewichtsverlies, 
kwaliteit van leven, effect van individuele dieet counseling, normale voedselinname en dysfagie 
bij HHT-patiënten, met als doel de voedingszorg van patiënten met HHT te verbeteren.
Gewichtsverlies
Hoofdstuk 2 beschrijft een prospectieve observationele studie naar de aanvang en mate 
van gewichtsverlies en de energie-inname bij patiënten met HHT, vanaf de diagnose tot 
zes maanden na de behandeling. Verschillende behandelvormen werden gevolgd in de tijd. 
De gewichtsverandering werd onderzocht bij 47 patiënten met een plaveiselcelcarcinoom 
van de mondholte, orofarynx of hypofarynx. Tijdens de behandeling hadden patiënten die 
een gecombineerde behandeling met chemotherapie en radiotherapie (chemoradiatie) en 
patiënten die alleen radiotherapie ondergingen gemiddeld het meeste gewichtsverlies ten 
opzichte van patiënten die alleen chirurgie of postoperatieve radiotherapie ondergingen. Vanaf 
het einde van de behandeling tot twee maanden na de behandeling hadden de patiënten 
die werden behandeld met (postoperatieve) radiotherapie aanzienlijk meer gewichtsverlies 
dan patiënten behandeld met chirurgie of chemoradiatie. Patiënten die primaire chirurgie 
ondergingen, hadden relatief weinig gewichtsverlies in de periode vanaf de diagnose tot het 
einde van de behandeling; dit gewicht stabiliseerde weer snel na de behandeling. De energie-
inname verminderde in de periode vanaf de diagnose tot het einde van de behandeling, in het 
bijzonder bij patiënten die werden behandeld met primaire (chemo) radiotherapie. Dit werd 
gevolgd door een toename tijdens de revalidatieperiode. In onze studie werd een correlatie 
gevonden tussen gewichtsverlies en verminderde energie-inname vanaf de diagnose tot 
de behandelperiode. Hoewel de gemiddelde inname tijdens de behandelperiode niet lager 
was dan de berekende energiebehoefte van 30-35 kcal per kg lichaamsgewicht (behalve bij 
chemoradiatie patiënten), was er toch sprake van gewichtsverlies.
Mede op basis van de resultaten van deze studie (hoofdstuk 2), wordt in ons ziekenhuis nu 
intensieve gestructureerde dieet counseling gegeven aan HHT-patiënten vanaf de diagnose 
tot in de revalidatieperiode.
Kwaliteit van leven
Hoofdstuk 3 beschrijft een prospectieve observationele studie over de relatie tussen 
ondervoeding en kwaliteit van leven (EORTC QoLQ-C30 en H&N 35 vragenlijsten) van 47 
patiënten met een tumor in de mondholte, orofarynx of hypofarynx op drie tijdstippen: het 
moment van de diagnose, het einde van de behandeling en zes maanden na de behandeling. 
Ondervoeding (gedefinieerd als gewichtsverlies ≥10% binnen 6 maanden) kwam voor bij 
respectievelijk 19%, 32% en 11% van de patiënten op het moment van de diagnose, op het einde 
van behandeling en zes maanden na de behandeling. Patiënten met ondervoeding scoorden 
significant slechter op functionele schalen, waaronder algehele kwaliteit van leven, cognitief 
functioneren en vermoeidheid. Ondervoede patiënten presteerden ook slechter (klinisch relevant) 
in de domeinen rol-functioneren en fysiek, emotioneel en sociaal functioneren. Ondervoede 
patiënten hadden aan het eind van de behandeling en/of 6 maanden na de behandeling 
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significant slechtere symptoomscores op het gebied van pijn, verminderde reuk- en smaak, 
droge mond, kleverig speeksel, hoesten, zich ‘ziek’ voelen en moeite met eten in het openbaar. 
 
Hoofdstuk 4 omvat een cross-sectionele exploratieve analyse van de kwaliteit van leven 
(EORTC QLQ-C30 en H&N35 vragenlijsten) van 52 patiënten met hoofd-halstumoren een 
maand na de behandeling voor drie verschillende behandelmodaliteiten;  radiotherapie, 
postoperatieve radiotherapie en chemoradiatie. De locatie van de tumor varieerde van 
nasofarynx tot larynx en het tumorstadium was III-IV. Het doel van deze studie was het in 
kaart brengen van de verschillende aspecten van kwaliteit van leven die om intensievere 
zorg en begeleiding vragen en de verschillen hierin tussen de drie behandelmodaliteiten. De 
resultaten lieten zien dat kleverig speeksel, gewichtsverlies, xerostomie, gebruik van pijnstillers 
en het gebruik van voedingssupplementen een maand na het einde van de behandeling 
gerapporteerd werden als de ergste symptomen c.q. het ergste resultaat van de behandeling 
(score>50). Patiënten die radiotherapie en chemoradiatie ondergingen, rapporteerden meer 
ernstige beperkingen dan patiënten die met postoperatieve radiotherapie behandeld werden. 
In het algemeen werden de grootste verschillen tussen de behandelmodaliteiten gevonden 
bij problemen met voedselinname (verlies aan eetlust, dysfagie, sondevoeding of voedings-
supplementen en/of gewichtsverlies) en verminderde orale functie (xerostomie, trismus, 
kleverig speeksel en/of tandproblemen). Dit benadrukt het belang van intensieve monitoring 
en continuering van ondersteunende zorg gedurende de eerste maanden van de follow-
upfase voor deze specifieke groep HHT-patiënten. 
Effect van individuele dieet counseling
Hoofdstuk 5 beschrijft een prospectieve cohort-studie van 38 patiënten met T2-4 tumoren 
in de mondholte, orofarynx en hypofarynx. Het doel van deze studie was het onderzoeken 
van de toegevoegde waarde van individuele dieet counseling ten opzichte van de standaard 
voedingszorg door een verpleegkundige. De uitkomstmaten van deze studie waren 
gewichtsverlies, body mass index (BMI) en ondervoeding, gemeten vóór, tijdens en na de 
behandeling. De individuele dieet counseling door een gespecialiseerd diëtist was gericht op 
het voorzien in de energie- en eiwitbehoeften van de patiënt. In vergelijking met de standaard 
voedingszorg leidde dieet counseling tot een significante daling van gewichtsverlies twee 
maanden na de behandeling. Het aantal patiënten met ondervoeding (≥5% gewichtsverlies 
binnen een maand) was twee maanden na de behandeling significant lager voor de groep met 
individuele dieet counseling, terwijl het aantal patiënten met ondervoeding in de groep die de 
standaard voedingszorg ontving toenam. 
 
Normale voedselinname en dysfagie
Hoofdstuk 6 beschrijft een cross-sectionele cohort-studie van de voedingsstatus, 
voedselinname en dysfagie bij 32 HHT-patiënten met stadium III-IV tumoren die behandeld 
waren met chemoradiatie na een mediane follow-up van 44 maanden. Op grond van de score 
op de Malnutrition Universal Screening Tool (MUST) had 19% van de patiënten een verhoogd 
risico op ondervoeding. In bijna alle gevallen was dit risico te wijten aan een lage BMI. Slechts 
één patiënt (3%) was ondervoed op basis van recent gewichtsverlies. De scores op de Eating 
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in Public-subschaal van de gevalideerde Performance Status Scale for Head and Neck 
Cancer Patients lieten zien dat geen van de overlevenden een “normaal dieet” kon gebruiken. 
Vierennegentig procent van de patiënten at zacht voedsel of voedsel met kleine aanpassingen 
in consistentie. Negentien procent (6/32) nam nog steeds energieverrijkte drinkvoeding tot 
zich en/of moest gebruik maken van sondevoeding. Dysfagie werd in 75% van de gevallen 
gediagnosticeerd aan de hand van de klinische beoordeling door de logopedist en in 57% aan 
de hand van videofluoroscopie. Bovendien hadden patiënten met een lage score op dysfagie 
(MD Anderson Dysphagia Inventory) significant minder aanpassingen in voedselconsistentie 
nodig.
Op basis van de bevindingen in dit proefschrift en eerder gepubliceerde studies, blijkt dat 
dysfagie wordt geassocieerd met zowel afgenomen (orale) voedselinname, toegenomen 
gewichtsverlies en verminderde kwaliteit van leven op de korte en lange termijn. Dysfagie 
wordt vaak gerapporteerd door patiënten met hoofd-halstumoren voor, tijdens en na de 
behandeling (hoofdstukken 3 en 4). Er zijn aanwijzingen in de literatuur dat de behandeling 
van dysfagie met preventieve sliktherapie een veelbelovende strategie is om de orale 
voedselinname te verbeteren en het gebruik van sondevoeding te verminderen. Vanuit deze 
achtergrond werd een gerandomiseerde klinische studie uitgevoerd die beschreven is in het 
volgende hoofdstuk.
Hoofdstuk 7 beschrijft een gerandomiseerde gecontroleerde studie waarin een 
multidisciplinaire interventie bestaande uit individuele dieet counseling gecombineerd 
met individuele sliktherapie vergeleken werd met primaire individuele dieet counseling 
(usual care). Honderdtwintig HHT-patiënten, 60 patiënten per groep, met een stadium II-IV 
plaveiselcelcarcinoom van nasofarynx tot larynx die behandeld werden met (postoperatieve) 
(chemo) radiotherapie werden beoordeeld op hun vermogen om een “normale voedselinname” 
tot zich te nemen. Normale voedselinname (NFI) werd gedefinieerd als een volledig orale 
voedselinname zonder energie- en/of eiwitverrijkte drinkvoedingen/supplementen of 
sondevoeding en zonder beperkingen in voedselconsistentie. Er werd geen significant verschil 
in NFI gevonden tussen de groep met dieet counseling en sliktherapie (interventiegroep) en 
de groep die alleen dieet counseling kreeg (controlegroep). Er was geen significant verschil 
in mate van dysfagie, kwaliteit van leven en voedingsstatus tussen de interventiegroep en 
de controlegroep. Wel bleek de interventiegroep een maand na de behandeling sneller te 
herstellen van dysfagie dan de controlegroep. Zes maanden na de behandeling werd NFI 
bereikt in 63% van de interventiegroep en 51% van de controlegroep. De incidentie van 
sondevoeding in de totale populatie was laag, slechts 20% van de patiënten had sondevoeding 
nodig; vrijwel alle patiënten met sondevoeding (88%) kregen een neusmaagsonde. 
Op basis van onze bevindingen zou individuele dieet counseling als volgt verder kunnen 
worden verbeterd.
Tijdens de behandeling kan dieet counseling (gericht op het waarborgen van de energie- 
en eiwitbehoefte van de patiënt) gewichtsverlies niet volledig voorkomen, maar wel kritisch 
gewichtsverlies minimaliseren. Dieet counseling zoals beschreven in hoofdstukken 5 en 
7 zou daarom op dezelfde wijze moeten worden voortgezet. Dieet counseling direct na de 
behandeling tot twee maanden na de behandeling resulteert in een significante vermindering 
van gewichtsverlies en ondervoeding, mits wordt voorzien in de totale behoefte aan 
energie en eiwit. Om ondervoeding verder terug te dringen, moet dieet counseling worden 
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geïntensiveerd in de periode direct na de behandeling tot ten minste twee maanden na de 
behandeling, omdat de incidentie van ondervoeding dan nog relatief hoog is. Dit zou op 
hetzelfde niveau moeten worden voortgezet zoals gedurende de behandelingsperiode (dat 
wil zeggen, op een wekelijkse basis tot twee maal per maand) tot ten minste twee maanden 
na behandeling. Sondevoeding moet daarbij niet worden vermeden, met name in de periode 
direct na de behandeling. Het is daarbij belangrijk dat HHT-patiënten bij aanvang van de 
behandeling verteld wordt dat sondevoeding een logisch en soms noodzakelijk onderdeel van 
de behandeling is. 
Voor de meeste patiënten heeft plaatsing van een neusmaagsonde, de voorkeur boven een 
profylactische gastrostomie, aangezien de gemiddelde verwachte periode van sondevoeding 
zes weken of korter is. Ten opzichte van patiënten met een gastrostomiesonde, hebben 
patiënten met een neusmaagsonde een betere orale voedselinname en een lagere incidentie 
van dysfagie doordat ze vaak langer zelf blijven eten/slikken. Hierdoor kunnen ze weer sneller 
op een normale wijze voedsel tot zich nemen, wat hun algemene kwaliteit van leven verbetert. 
Om de effectiviteit van individuele dieet counseling verder te verbeteren, zou toekomstig 
onderzoek gericht moeten zijn op het verder verminderen van gewichtsverlies in de periode 
na de behandeling met een stabilisatie danwel toename van de spiermassa. Daarnaast zou 
dieet counseling zich moeten richten op het bereiken van een vrijwel normale voedselinname, 
om zo de negatieve sociale aspecten van een niet-normale voedselinname te minimaliseren. 
Aanbeveling voor toekomstig onderzoek
Kanker cachexie
De mate van gewichtsverlies bij HHT patiënten is vaak het resultaat van verminderde 
voedselinname, door symptomen zoals mucositis, xerostomie, dysfagie en verminderde 
geur en smaak, op basis van hongeren en/of door inflammatie/ kankercachexia. De 
werkelijke incidentie van kankercachexie bij HHT-patiënten is niet bekend. Interventies om 
kankercachexie te beperken of te voorkomen met voedings interventies, medicamenteuze 
behandelingen (bijvoorbeeld met hormonale of andere eetlustopwekkende middelen zoals 
ghreline) en nutraceuticals (bijv. eicosapentaeenzuur) zouden mogelijk enige verbetering 
kunnen geven.
 
Spiermassa
Een tweede doelstelling voor de verdere verbetering van dieet counseling is om het vergroten 
van de functionele spiermassa van de patiënt. Een gecombineerde behandeling van 
lichaamsbeweging en adequate voedingsinterventie zouden hierin ondersteunend kunnen 
zijn. Lichaamsbeweging kan de lichaamssamenstelling verbeteren (bijv. de vetvrije massa 
vergroten) en aldus de algehele kwaliteit van leven verhogen, vermoeidheid verminderen 
en het lichamelijk functioneren van ondervoede patiënten verbeteren. Gerandomiseerde 
gecontroleerde studies zijn nodig om het effect van een combinatie van lichaamsbeweging 
en adequate dieet counseling (volwaardige energie- en eiwitbehoefte) in HHT patiënten te 
evalueren tijdens en na de behandeling.
 
128
Normale voedselinname
Ten slotte zouden vervolgstudies zich niet alleen op het handhaven en/of verbeteren van de 
voedingstoestand van HHT-patiënten moeten richten, maar ook op het bevorderen van het 
herstel van de normale voedselinname om hiermee het genot en het sociale aspect van eten 
te verbeteren. 
Een verdere verbetering van normale voedselinname kan worden bereikt door het verminderen 
van de behoefte aan drinkvoeding/ voedings supplementen en voeding met een aangepaste 
consistentie met name in de revalidatiefase, met behoud van een goede voedingstoestand. 
Dit zou kunnen leiden tot een verbetering van de kwaliteit van leven en mogelijk ook tot 
kostenbesparingen. Om patiënten te helpen omgaan met alle overige problemen rondom 
het eten, zouden naast fysieke behandelmethoden (bijvoorbeeld sliktherapie) ook holistische 
interventies op het gebied van de psychische en/of sociale aspecten van het eten moeten 
worden ontwikkeld en onderzocht om patiënten te helpen omgaan met alle resterende 
problemen rondom eten. Deze levenslange aspecten verdienen nadere aandacht in verder 
onderzoek en opleidingen van diëtisten en andere paramedische beroepsbeoefenaren die 
werken met HHT-patiënten.
Conclusie
Gewichtsverlies en ondervoeding tijdens en na de behandeling komen vaak voor bij HHT-
patiënten met tumorstadiëring II-IV. De mate van ondervoeding neemt toe aan het einde 
van de behandeling en in de vroege revalidatieperiode, met name bij patiënten die worden 
behandeld met (chemo)radiotherapie. Ondervoeding wordt geassocieerd met een significant 
slechtere algehele kwaliteit van leven, vermoeidheid en verminderd cognitief functioneren. 
Individuele dieet counseling is een effectieve therapie om gewichtsverlies en ondervoeding 
te beperken.
Door intensieve behandelingsstrategieën hebben veel HHT-patiënten symptomen die een 
normale voedselinname belemmeren. Dit kan leiden tot ondervoeding en verminderde 
kwaliteit van leven. Dysfagie is hierin een van de meest prominente symptomen. Ondanks 
verwachtingen, blijkt een combinatie van sliktherapie en individuele dieet counseling niet te 
leiden tot een sneller herstel van de normale voedselinname bij HHT-patiënten.
129
Samenvatting

Dankwoord
132
Het onderzoek blijkt voor mij een hele goede keuze! Het was een heel nieuw gebied en een 
groot avontuur, ik heb hier de afgelopen jaren met veel plezier en voldoening aan gewerkt!! 
Mede door de fijne contacten met patiënten en de prettige samenwerking op de werkvloer 
met alle andere betrokken hulpverleners heeft dit onderzoek kunnen plaatsvinden. We 
zagen knelpunten in de voedingszorg en door de samenwerking en stimulans van de hoofd 
halsketen heeft dit onderzoek uiteindelijk geleid tot dit resultaat! Daar ben ik trots op!! Ik heb 
met eigen ogen gezien hoe we de voedingszorg voor deze patiëntenpopulatie op een hoog 
niveau hebben gebracht en wat we voor deze patiëntengroep kunnen betekenen.
Ik wil graag iedereen bedanken die mij in dit promotietraject hebben bijgestaan. Hierbij wil ik 
graag een aantal personen in het bijzonder noemen:
Beste patiënten, bedankt voor jullie bereidheid om deel te nemen aan mijn onderzoeken en 
de bijdrage die jullie doordoor zelf hebben geleverd aan alle ontwikkelingen. 
Beste professor Merkx, Beste Thijs, na een aantal jaren patiëntenzorg was jij degene die 
mij het vertrouwen heeft gegeven om dit promotietraject in te gaan! Je bent altijd toegankelijk 
geweest en dat maakte de afgelopen jaren erg prettig. Je had steeds een oplossing voor hoe 
verder. Ons overleg was niet alleen inhoudelijk zinvol maar ook gezellig. Op vrijdag middag 
even een kop koffie om de voortgang te bespreken, ik zal het missen. Bedankt voor alle 
ondersteuning, enthousiasme, geduld en humor. Dank dat je mijn promotor bent geweest en 
ik hoop dat we nog lang mogen samenwerken. 
Beste professor Kaanders, Beste Hans, bedankt voor al jouw kritische en waardevolle 
input. Jouw rustige overwogen benadering heeft me erg geholpen. Ik heb veel waardering 
voor jou als klinisch onderzoeker. Je hebt er mede voor gezorgd dat onze gerandomiseerde 
studie organisatorisch goed van de grond is gekomen. Teksten werden elke keer beter 
met jouw opmerkingen. Even een kort telefoontje en ik kon weer verder. Bedankt voor de 
samenwerking, hopelijk blijft deze zo bestaan.
Beste professor Drenth, Beste Joost, Je hebt me vanaf het begin af aan gesteund. Je 
stond steeds klaar ondanks jouw overvolle agenda. Van jouw wetenschappelijke ervaring 
heb ik veel geleerd, in de werkbesprekingen maar ook daarbuiten. Dank voor jouw possitieve 
en kritische inbreng. Hoop dat we deze samenwerking verder kunnen uitbreiden en het 
voedingsonderzoek binnen de afdeling MDL verder op de kaart kunnen zetten.
Beste dr. Wanten, Beste Geert, ik ken jou al vanuit de periode van het voedingsteam. Je 
gaat slagvaardige te werk en staat altijd klaar bij vragen. Jouw snelle reacties op mails en 
vragen heb ik heel fijn gevonden. De frisse blik op teksten, alle tips en suggesties waren van 
harte welkom. Hoop dat we in de toekomst het voedingskundig onderzoek binnen de afdeling 
MDL verder kunnen uitbreiden. 
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Beste Ellen, jij hebt me kennis laten maken met het voedingsonderzoek; methodologie en 
de statistiek. Daar ben ik je heel dankbaar voor! De gesprekken met jou waren altijd heel 
verhelderend. Je hebt me steeds gesteund en gestimuleerd om verder te gaan. Bedankt 
daarvoor!
Mede auteurs, en in het bijzonder Ton Naber, Jaap van Binsbergen, Heidi Rütten, Robert 
Takes, Carla van Herpen en Jan Hendriks hartelijk dank voor jullie bijdrage aan de artikelen. 
Leden van de manuscriptcommissie, Beste Prof. Dr. Theo van Achterberg, Prof. Dr. Ellen 
Kampman en Prof. Dr. Henri Marres, graag wil ik jullie bedanken voor jullie tijd en de kritische 
beoordeling van dit manuscript. 
Beste Marjo, bedankt voor jouw luisterend oor op de momenten dat ik het zwaar had en voor 
de flexibiliteit die je me geboden hebt tijdens dit promotietraject. Je bent altijd erg enthousiast 
geweest en door met me mee te denken is het gelukt om de werkzaamheden voor onderzoek 
en patiëntenzorg te combineren.
Lieve Monique en Hester, samen met jullie hebben we de basis gelegd voor voedingszorg van 
de hoofd halsoncologische patiënt. Daar ben ik trots op! Hester ik waardeer jouw creativiteit 
en enthousiasme. Monique jouw gedrevenheid en collegialiteit bewonder ik. Bedankt voor 
jullie geweldige ondersteuning en feedback tijdens het onderzoek. Wat leuk dat jullie mijn 
paranimfen willen zijn! 
Mirjam, Heleen, Renée, Annemieke, Mariska, Sanne en Iris, bedankt voor jullie waardevolle 
inzet de afgelopen jaren. We hebben een gedreven en gezellig team! Van patiënten hoor ik 
vaak terug dat ze zo blij zijn met onze ondersteuning.
Natuurlijk ook alle andere collega´s van de afdeling MDL- diëtetiek! Bedankt dat jullie zo´n 
fijne collega´s zijn en voor de interesse die jullie hebben getoond voor het onderzoek waar ik 
mee bezig ben geweest. 
Onderzoekers van de afdeling MDL, het is prettig om met jullie van gedachten te wisselen. 
Het doen van onderzoek ik natuurlijk heel leuk maar af en toe ook wel wat eenzaam. Dan is 
het fijn om jullie te spreken.
Beste Jacqueline, wat fijn dat ik jou tijdens mijn promotietraject heb leren kennen. Het was 
heel prettig om met jou samen te werken! Wat heb ik lol gehad met jou! Dat was een zeer 
welkome afwisseling in het serieuzere werk waar ik steeds weer veel energie van kreeg.
Beste Hanneke, met jou samen is mede het slikonderzoek tot stand gekomen. We hebben 
een grote stap gezet! De discussie´s en overwegingen met jou heb ik als zeer waardevol 
ervaren. Je hebt grootste ideeën en bent een echte onderzoeker met hart voor je werk!
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Beste Anne, Emmelien, Pauline en Simone, wat zijn jullie een geweldig team logopedisten! 
Jullie inzet en flexibiliteit om onze FOCISD-studie tot het laatst toe tot in de puntjes te 
volbrengen waardeer ik enorm. Bedankt daarvoor.
Studenten van de opleiding voeding en gezondheid van de WUR: Gelagister, Lilian, Koko, 
Lowela, Anouk en Ilse jullie hebben onvoorstelbaar veel werk verricht. Dank voor jullie tijd 
en de waardevolle opdrachten die jullie hebben uitgevoerd.
Beste PWHHT, wat een prettige en gezellige werkgroep hebben we! Het was een plezier om 
met jullie samen te werken. Wat leerzaam om de congressen mee te organiseren. Bedankt 
voor de fijne tijd!
Beste Marianne, Maurice, Wilma, Germa, Janneke, Lisette, Truus, Heidi, Nifja, Jaya, 
Jacqueline, Heleen, Annemieke, Edith, Lotte, Gidi, Fred, Marion en alle andere 
verpleegkundigen, voedingsassistenten, paramedici, secretaresses en specialisten 
van de hoofd-halsoncologische keten wat is het prettig om met jullie samen te werken. De 
flexibele inzet van jullie en de gezellige praatjes op zijn tijd maken het extra plezierig om hier 
te werken!
Lieve vriendinnen en vrienden, bedankt voor alle gezellige en ontspannen momenten en 
voor de interesse die jullie getoond hebben. Lieve Marjon, Yvon en Brigit, we hebben de 
afgelopen decennia al heel wat levenservaring gedeeld. Bedankt voor de leuke, gezellige, 
mooie en bijzondere momenten die ik met jullie mocht delen, ik hoop dat we in de toekomst 
nog veel mooie momenten zullen beleven. 
Lieve schoonfamilie, Theo en Corrie bedankt voor jullie gezelligheid en voor het feit dat 
jullie zo´n lieve opa en oma zijn. Bedankt voor alle momenten dat jullie klaar staan. Lieve 
Mirjam, Erik, Julie, Ruben, Ernie en Janick wat fijn dat jullie familie zijn! 
Lieve familie, lieve pap en mam, bedankt voor jullie onvoorwaardelijke steun en de fijne 
onbezorgde jeugd die ik heb gehad! Hierdoor heb ik me kunnen ontwikkelen tot de persoon 
die ik nu ben! Bedankt daarvoor. Ik vind het geweldig om te zien hoe jullie van Jada en Evan 
kunnen genieten. Ik hou van jullie! Lieve Jan, Karina, Jan, Nienke, Lotte, Wouter, Sanne 
en Diede wat fijn dat jullie familie zijn!
Lieve Archie, Wat hebben we het fijn samen! Wat genieten we samen en met de kinderen, 
wij zijn een hecht team. Je hebt me altijd gestimuleerd om deze uitdaging aan te gaan en 
te volbrengen. Bedankt voor alle steun, tijd en ruimte die je me tijdens dit promotietraject 
gegeven hebt. Ik hou van jou!
Lieve Jada en Evan, wat ben ik trots op jullie! Ik geniet van jullie vrolijkheid en enthousiasme. 
Wat is het gezellig om samen te spelen of er samen op uit te gaan. Ik vind het fantastisch om 
jullie op te zien groeien en om samen met jullie de wereld te ontdekken. Wat hou ik enorm 
veel van jullie!!
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